<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02807844</url>
  </required_header>
  <id_info>
    <org_study_id>CMCS110Z2102</org_study_id>
    <secondary_id>2016-000210-29</secondary_id>
    <nct_id>NCT02807844</nct_id>
  </id_info>
  <brief_title>Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies</brief_title>
  <official_title>A Phase Ib/II, Open Label, Multicenter Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study of MCS110 with PDR001 was to characterize the safety, tolerability,&#xD;
      pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of the combination of&#xD;
      MCS110 with PDR001 in adult patients with solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Combined treatment with MCS110 and PDR001 was expected to result in Tumor-associated&#xD;
      macrophages (TAM) depletion, enhanced T-cell activation and synergistic antitumor activity in&#xD;
      the clinical setting.&#xD;
&#xD;
      This study was a Phase Ib/II, multi-center, open label study starting with a Phase Ib dose&#xD;
      escalation part followed by a Phase II part. MCS110 and PDR001 were administered i.v. Q3W&#xD;
      until the patient experienced unacceptable toxicity, progressive disease as per irRC and/or&#xD;
      treatment was discontinued at the discretion of the investigator or the patient. Patients&#xD;
      were not to discontinue treatment based on progressive disease per Response evaluation&#xD;
      criteria in solid tumors (RECIST) v1.1. During the Phase Ib part of the study, cohorts of&#xD;
      patients were treated with increasing doses of MCS110 and PDR001 every 3 weeks until a&#xD;
      Recommended Phase 2 Dose (RP2D) was determined for this treatment combination.&#xD;
&#xD;
      To assure that the combination RP2D did not exceed the Maximum tolerated dose (MTD), the&#xD;
      combination MCS110 and PDR001 dose escalation was guided by a Bayesian logistic regression&#xD;
      model (BLRM) with overdose control (EWOC) principle based on dose limiting toxicity data in&#xD;
      the context of available safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) information.&#xD;
      Once the MTD and/or RP2D was declared, additional patients were enrolled in the Phase II part&#xD;
      in order to assess the preliminary anti-tumor activity of MCS110 in combination with PDR001&#xD;
      in anti-PD1/PD-L1-naive triple negative breast cancer (TNBC), pancreatic (PC), endometrial&#xD;
      carcinoma (EC) and anti PD1/PD-L1-resistance melanoma (ME).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 29, 2016</start_date>
  <completion_date type="Actual">June 4, 2020</completion_date>
  <primary_completion_date type="Actual">June 4, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase Ib: Percentage of Participants With Adverse Events, as a Measure of Safety</measure>
    <time_frame>From start of treatment to a maximum timeframe of 116.4 weeks for phase Ib</time_frame>
    <description>Phase Ib: To characterize the safety and tolerability of MCS110 in combination with PDR001 in patients with advanced solid malignancies and to identify a recommended dose combination for Phase II.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase II : Overall Response Rate (ORR) - Per RECIST v1.1</measure>
    <time_frame>4 years</time_frame>
    <description>Overall Response Rate (ORR) is defined as the proportion of patients with a best overall response assessed by CT scan or MRI of complete response (CR), disappearance of all measurable and non-measurable lesions or partial response (PR), at least a 30% decrease in the sum of diameter of all measurable lesions, taking as reference the baseline sum of diameters,. based on local Investigator assessment, as per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase II : Bayesian Inference of Overall Response Rate (ORR) - Per RECIST v1.1 - Mean</measure>
    <time_frame>4 years</time_frame>
    <description>Overall Response Rate (ORR) is defined as the proportion of patients with a best overall response assessed by CT scan or MRI of complete response (CR), disappearance of all measurable and non-measurable lesions or partial response (PR), at least a 30% decrease in the sum of diameter of all measurable lesions, taking as reference the baseline sum of diameters,. based on local Investigator assessment, as per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) - mean (FAS)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase II: Clinical Benefit Rate (Complete Response (CR) or Partial Response (PR) or Stable Disease (SD) &gt; 4 Month)) - Per RECIST v1.1</measure>
    <time_frame>4 years</time_frame>
    <description>Phase II: Clinical Benefit Rate (Complete response (CR) or Partial response (PR) or Stable disease (SD) &gt; 4 month)) per investigator based on Response evaluation criteria in solid tumors (RECIST) v1.1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase II: Bayesian Inference of Clinical Benefit Rate - Per RECIST v1.1- Mean</measure>
    <time_frame>4 years</time_frame>
    <description>Phase II: Clinical Benefit Rate (Complete response (CR) or Partial response (PR) or Stable disease (SD) &gt; 4 month)) per investigator based on Response evaluation criteria in solid tumors (RECIST) v1.1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase Ib: Planned Dose Intensity - MCS110</measure>
    <time_frame>Measured up to a max of 112.4 weeks</time_frame>
    <description>To characterize the tolerability of MCS110 given in combination with PDR001 and to identify a recommended dose combination for Phase II. Planned dose intensity for MCS110 is cumulative planned dose (mg/kg)/ number of doses scheduled per protocol during treatment period (i.e., this is equivalent to planned dose level).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase Ib: Relative Dose Intensity - MCS110</measure>
    <time_frame>Measured up to a max of 112.4 weeks</time_frame>
    <description>To characterize the tolerability of MCS110 given in combination with PDR001 and to identify a recommended dose combination for Phase II. Relative dose intensity (%) is 100 × dose intensity (mg/kg/3wks)/planned dose intensity (mg/kg/3wks).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase Ib: Planned Dose Intensity - PDR001</measure>
    <time_frame>Measured up to a max of 112.4 weeks</time_frame>
    <description>To characterize the tolerability of MCS110 given in combination with PDR001 and to identify a recommended dose combination for Phase II. Planned dose intensity for PDR001 (mg/3wks) is planned cumulative dose (mg)/ number of doses scheduled per protocol during treatment period (i.e., this is equivalent to planned dose level).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase Ib: Relative Dose Intensity - PDR001</measure>
    <time_frame>Measured up to a max of 112.4 weeks</time_frame>
    <description>To characterize the tolerability of MCS110 given in combination with PDR001 and to identify a recommended dose combination for Phase II. Relative dose intensity (%) is 100 × dose intensity (mg/3wks)/planned dose intensity (mg/3wks).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase Ib: Number of Participants With Dose Reductions</measure>
    <time_frame>Measured up to a max of 112.4 weeks</time_frame>
    <description>To characterize the tolerability of MCS110 given in combination with PDR001 and to identify a recommended dose combination for Phase II.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase Ib: Number of Dose Interruptions Per Participant</measure>
    <time_frame>Measured up to a max of 112.4 weeks</time_frame>
    <description>To characterize the tolerability of MCS110 given in combination with PDR001 and to identify a recommended dose combination for Phase II.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase Ib: Number of Subjects With at Least One Dose Interruption</measure>
    <time_frame>Measured up to a max of 112.4 weeks</time_frame>
    <description>To characterize the tolerability of MCS110 given in combination with PDR001 and to identify a recommended dose combination for Phase II.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase Ib: Number of Participants With Dose Limiting Toxicities (DLTs) During the First 2 Cycles of Study Treatment</measure>
    <time_frame>the first 2 cycles of study treatment; cycle = 21 days (i.e., at day 42)</time_frame>
    <description>Phase Ib: Dose limiting toxicities occurring during the first 2 cycles by system organ class, preferred term and maximum grade for Phase Ib. The National Cancer Institute Common Terminology Criteria for Adverse events (NCI CTCAE) version 4.03 was used for all grading.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase II : Overall Response Rate (ORR) - Per irRC</measure>
    <time_frame>4 years</time_frame>
    <description>Phase II: Overall Response Rate (Complete response (CR) or Partial response (PR)) (with confirmation) as per investigator based on immune related Response criteria (irRC) (FAS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase Ib: Overall Response Rate (ORR)</measure>
    <time_frame>4 years</time_frame>
    <description>Phase Ib: Overall Response Rate (Complete response (CR) or Partial response (PR)), per RECIST v1.1 and per immune related Response criteria (irRC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II : Bayesian Inference of Overall Response Rate (ORR) - Per irRC - Mean</measure>
    <time_frame>4 years</time_frame>
    <description>Phase II: Overall Response Rate (Complete response (CR) or Partial response (PR)) (with confirmation) as per investigator based on immune related Response criteria (irRC)- mean (FAS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Clinical Benefit Rate (CBR)</measure>
    <time_frame>4 years</time_frame>
    <description>Phase 1b: Clinical Benefit Rate (Complete response (CR) or Partial response (PR) or Stable disease (SD) &gt; 4 month)) per RECIST v1.1 and per immune related Response criteria (irRC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: Clinical Benefit Rate (Complete Response (CR) or Partial Response (PR) or Stable Disease (SD) &gt; 4 Month)) - Per irRC</measure>
    <time_frame>4 years</time_frame>
    <description>Phase II: Clinical Benefit Rate (Complete response (CR) or Partial response (PR) or Stable disease (SD) &gt; 4 month)) per immune related Response criteria (irRC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: Bayesian Inference of Clinical Benefit Rate - Per irRC - Mean</measure>
    <time_frame>4 years</time_frame>
    <description>Phase II: Clinical Benefit Rate (Complete response (CR) or Partial response (PR) or Stable disease (SD) &gt; 4 month)) per investigator based on immune related Response criteria (irRC)- mean (FAS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b and Phase II: Progression Free Survival Based on Investigator Assessment as Per RECIST v1.1 and Per Immune Related Response Criteria (irRC) - Using Kaplan-Meier Method - Median</measure>
    <time_frame>Up to year 4</time_frame>
    <description>Phase 1b and Phase II: Progression Free Survival. Progression is defined as a 20% increase in the sum of diameter of measurable lesions taking as reference the smallest sum of diameter recorded at or after baseline, or worsening of non-measurable lesions or the appearance of new lesions, using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) or Per Immune Related Response Criteria (irRC). Unlike RECIST 1.1, PD per irRC requires confirmation at a new assessment after at least 4 weeks - using Kaplan-Meier method - Median.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b and Phase II: Overall Survival - Using Kaplan-Meier Method - Median</measure>
    <time_frame>Up to year 4</time_frame>
    <description>Phase 1b and Phase II: Overall Survival - using Kaplan-Meier method - Median</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b and Phase II: Duration of Response (DOR)</measure>
    <time_frame>4 years</time_frame>
    <description>Phase 1b and Phase II: Duration of Response (DOR) per RECIST v1.1 and per immune related Response criteria (irRC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b and Phase II: Disease Control Rate (DCR)</measure>
    <time_frame>4 years</time_frame>
    <description>Phase 1b and Phase II: Disease Control Rate (Complete response (CR) or Partial response (PR) or Stable disease (SD) &gt; 4 month)) per RECIST v1.1 and per immune related Response criteria (irRC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: Percentage of Participants With Adverse Events, as a Measure of Safety</measure>
    <time_frame>From start of treatment to a maximum timeframe of 92.4 weeks for phase II.</time_frame>
    <description>Phase II: To further characterize the safety and tolerability of MCS110 given in combination with PDR001</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase Ib and Phase II: Immunogenicity MCS110</measure>
    <time_frame>4 years</time_frame>
    <description>Phase Ib and Phase II: Presence of anti-MCS110 antibodies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase Ib and Phase II: Immunogenicity PDR001</measure>
    <time_frame>4 years</time_frame>
    <description>Phase Ib and Phase II: Presence of anti-PDR001 antibodies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase Ib and Phase II: Pharmacokinetics of MCS110 - AUClast and AUCinf</measure>
    <time_frame>cycle 1 (day 21) and cycle 4 (day 84)</time_frame>
    <description>Phase Ib and Phase II: PK Parameters - AUClast, which is the AUC from time zero to the last measurable concentration sampling time (tlast) (mass × time&#xD;
× volume-1); and AUCinf, which is the AUC from time zero to infinity (mass × time × volume-1) - MCS110</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase Ib and Phase II: Pharmacokinetics of PDR001 - AUClast and AUCinf</measure>
    <time_frame>cycle 1 (day 21) and cycle 4 (day 84)</time_frame>
    <description>Phase Ib and Phase II: Pharmacokinetics (PK) Parameters - AUClast, which is the AUC from time zero to the last measurable concentration sampling time (tlast) (mass × time&#xD;
× volume-1); and AUCinf, which is the AUC from time zero to infinity (mass × time × volume-1) and AUCinf - PDR001</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase Ib and Phase II: Pharmacokinetics of MCS110 - Cmax and Clast</measure>
    <time_frame>cycle 1 (day 21) and cycle 4 (day 84)</time_frame>
    <description>Phase Ib and Phase II: PK Parameters - Cmax, which is the maximum (peak) observed plasma, blood, serum, or other body fluid drug concentration after single dose administration (mass × volume-1); and Clast - MCS110</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase Ib and Phase II: Pharmacokinetics of PDR001 - Cmax and Clast</measure>
    <time_frame>cycle 1 (day 21) and cycle 4 (day 84)</time_frame>
    <description>Phase Ib and Phase II: PK Parameters - Cmax, which is the maximum (peak) observed plasma, blood, serum, or other body fluid drug concentration after single dose administration (mass × volume-1); and Clast - PDR001</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase Ib and Phase II: Pharmacokinetics of MCS110 - Tmax</measure>
    <time_frame>cycle 1 (day 21) and cycle 4 (day 84)</time_frame>
    <description>Phase Ib and Phase II: PK Parameters - Tmax, which is the time to reach maximum (peak) plasma, blood, serum, or other body fluid drug concentration after single dose administration (time) - MCS110</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase Ib and Phase II: Pharmacokinetics of PDR001 - Tmax</measure>
    <time_frame>cycle 1 (day 21) and cycle 4 (day 84)</time_frame>
    <description>Phase Ib and Phase II: PK Parameters - Tmax, which is the time to reach maximum (peak) plasma, blood, serum, or other body fluid drug concentration after single dose administration (time) - PDR001</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase Ib and Phase II: Pharmacokinetics of MCS110 - T1/2</measure>
    <time_frame>cycle 1 (day 21) and cycle 4 (day 84)</time_frame>
    <description>Phase Ib and Phase II: PK Parameters - T1/2, which is the terminal half-life associated with the terminal slope of a semi logarithmic concentration time curve (time) - MCS110</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase Ib and Phase II: Pharmacokinetics of PDR001 - T1/2</measure>
    <time_frame>cycle 1 (day 21) and cycle 4 (day 84)</time_frame>
    <description>Phase Ib and Phase II: PK Parameters - T1/2, which is the terminal half-life associated with the terminal slope of a semi logarithmic concentration time curve (time) - PDR001</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase Ib and Phase II: Pharmacokinetics of MCS110 - CL</measure>
    <time_frame>cycle 1 (day 21) and cycle 4 (day 84)</time_frame>
    <description>Phase Ib and Phase II: PK Parameters - CL, which is the total body clearance of drug from the plasma (volume × time-1) - MCS110</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase Ib and Phase II: Pharmacokinetics of PDR001 - CL</measure>
    <time_frame>cycle 1 (day 21) and cycle 4 (day 84)</time_frame>
    <description>Phase Ib and Phase II: PK Parameters - CL, which is the total body clearance of drug from the plasma (volume × time-1) - PDR001</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase Ib and Phase II: Pharmacokinetics of MCS110 - Vz</measure>
    <time_frame>cycle 1 (day 21) and cycle 4 (day 84)</time_frame>
    <description>Phase Ib and Phase II: PK Parameters - Vz, which is the apparent volume of distribution during terminal phase (volume) - MCS110</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase Ib and Phase II: Pharmacokinetics of PDR001 - Vz</measure>
    <time_frame>cycle 1 (day 21) and cycle 4 (day 84)</time_frame>
    <description>Phase Ib and Phase II: PK Parameters - Vz, which is the apparent volume of distribution during terminal phase (volume) - PDR001</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase Ib and Phase II: Pharmacokinetics of MCS110 - Accumulation Ratio (AR)</measure>
    <time_frame>cycle 4 (day 84)</time_frame>
    <description>Phase Ib and Phase II: PK Parameters - Accumulation ratio (AR), which is the AUClast (multiple Dose)/AUClast (single dose) (for cycle 4 only) - MCS110</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase Ib and Phase II: Pharmacokinetics of PDR001 - Accumulation Ratio (AR)</measure>
    <time_frame>cycle 4 (day 84)</time_frame>
    <description>Phase Ib and Phase II: PK Parameters - Accumulation ratio (AR), which is the AUClast (multiple Dose)/AUClast (single dose) (for cycle 4 only) - PDR001</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase Ib and Phase II: All Collected Deaths</measure>
    <time_frame>For ontreatment deaths: up to maximum timeframe of 116.4 weeks for phase Ib and 92.4 weeks for phase II. For total deaths: up to 3.8 years</time_frame>
    <description>On treatment deaths are reported from the start of treatment until end of study treatment plus 30 days, up to maximum duration of 116.4 weeks for phase Ib and 92.4 weeks for phase II. Deaths post treatment survival follow up are reported after the on-treatment period, up to a maximum timeframe of 46 months (3.8 years).</description>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Actual">141</enrollment>
  <condition>Triple Negative Breast Cancer</condition>
  <condition>Pancreatic Carcinoma</condition>
  <condition>Melanoma</condition>
  <condition>Endometrial Carcinoma</condition>
  <arm_group>
    <arm_group_label>Ph Ib: MCS110 1 mg/kg Q3W + PDR001 100 mg Q3W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase Ib: MCS110 1 mg/kg every 3 weeks (Q3W) + PDR001 100 mg Q3W</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ph Ib: MCS110 3 mg/kg Q3W + PDR001 100 mg Q3W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase Ib: MCS110 3 mg/kg Q3W + PDR001 100 mg Q3W</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ph Ib: MCS110 3 mg/kg Q3W + PDR001 300 mg Q3W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase Ib: MCS110 3 mg/kg Q3W + PDR001 300 mg Q3W</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ph Ib: MCS110 5 mg/kg Q3W + PDR001 300 mg Q3W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase Ib: MCS110 5 mg/kg Q3W + PDR001 300 mg Q3W</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ph Ib: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase Ib: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ph Ib: MCS110 10 mg/kg Q3W + PDR001 300 mg Q3W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase Ib: MCS110 10 mg/kg Q3W + PDR001 300 mg Q3W</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - TNBC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Triple negative breast cancer (TNBC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - PC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Pancreatic cancer (PC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - EC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Endometrial cancer (EC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - ME</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Melanoma (ME)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MCS110</intervention_name>
    <description>MCS110 and PDR001 - for administration once every 3 weeks via i.v. infusion.</description>
    <arm_group_label>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - EC</arm_group_label>
    <arm_group_label>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - ME</arm_group_label>
    <arm_group_label>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - PC</arm_group_label>
    <arm_group_label>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - TNBC</arm_group_label>
    <arm_group_label>Ph Ib: MCS110 1 mg/kg Q3W + PDR001 100 mg Q3W</arm_group_label>
    <arm_group_label>Ph Ib: MCS110 10 mg/kg Q3W + PDR001 300 mg Q3W</arm_group_label>
    <arm_group_label>Ph Ib: MCS110 3 mg/kg Q3W + PDR001 100 mg Q3W</arm_group_label>
    <arm_group_label>Ph Ib: MCS110 3 mg/kg Q3W + PDR001 300 mg Q3W</arm_group_label>
    <arm_group_label>Ph Ib: MCS110 5 mg/kg Q3W + PDR001 300 mg Q3W</arm_group_label>
    <arm_group_label>Ph Ib: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W</arm_group_label>
    <other_name>colony-stimulating factor-1 [CSF-1])</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PDR001</intervention_name>
    <description>MCS110 and PDR001 - for administration once every 3 weeks via i.v. infusion.</description>
    <arm_group_label>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - EC</arm_group_label>
    <arm_group_label>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - ME</arm_group_label>
    <arm_group_label>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - PC</arm_group_label>
    <arm_group_label>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - TNBC</arm_group_label>
    <arm_group_label>Ph Ib: MCS110 1 mg/kg Q3W + PDR001 100 mg Q3W</arm_group_label>
    <arm_group_label>Ph Ib: MCS110 10 mg/kg Q3W + PDR001 300 mg Q3W</arm_group_label>
    <arm_group_label>Ph Ib: MCS110 3 mg/kg Q3W + PDR001 100 mg Q3W</arm_group_label>
    <arm_group_label>Ph Ib: MCS110 3 mg/kg Q3W + PDR001 300 mg Q3W</arm_group_label>
    <arm_group_label>Ph Ib: MCS110 5 mg/kg Q3W + PDR001 300 mg Q3W</arm_group_label>
    <arm_group_label>Ph Ib: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent prior to any procedures&#xD;
&#xD;
          -  Phase Ib part: Adult patients with advanced melanoma, endometrial carcinoma,&#xD;
             pancreatic or TNBC, with measurable or non-measurable disease who have progressed&#xD;
             despite standard therapy or are intolerant of standard therapy, or for whom no&#xD;
             standard therapy exists.&#xD;
&#xD;
          -  Phase II part: Adult patients with advanced solid tumors who have received standard&#xD;
             therapy (no more than 3 prior lines of treatment) or are intolerant of standard&#xD;
             therapy, have progressed following their last prior therapy, and fit into one of the&#xD;
             following groups:&#xD;
&#xD;
               -  Group 1: TNBC who did not receive prior anti-PD-1/PD-L1 treatment&#xD;
&#xD;
               -  Group 2: Pancreatic adenocarcinoma who did not receive prior anti-PD-1/PD-L1&#xD;
                  treatment&#xD;
&#xD;
               -  Group 3: Endometrial carcinoma who did not receive prior anti-PD-1/PD-L1&#xD;
                  treatment&#xD;
&#xD;
               -  Group 4: Melanoma who progressed on prior anti-PD-1/PD-L1 treatment.&#xD;
&#xD;
        Main Exclusion Criteria:&#xD;
&#xD;
          -  Patients with the following:&#xD;
&#xD;
               -  Symptomatic central nervous system (CNS) metastases or those requiring local&#xD;
                  CNS-directed therapy.&#xD;
&#xD;
               -  Abnormal liver, renal, or blood lab values.&#xD;
&#xD;
               -  Impaired cardiac function or clinically significant cardiac disease.&#xD;
&#xD;
               -  Active autoimmune disease or documented autoimmune disease within 3 years of&#xD;
                  screening.&#xD;
&#xD;
               -  Active infection requiring antibiotic therapy.&#xD;
&#xD;
               -  Known HIV, active hepatitis B or C virus.&#xD;
&#xD;
               -  Concurrent malignant disease.&#xD;
&#xD;
          -  Patients who received systemic anticancer therapy, major surgery, or radiotherapy&#xD;
             within 2 weeks of study treatment, or live vaccines within 4 weeks of study treatment.&#xD;
&#xD;
          -  Patients requiring chronic treatment with systemic steroid therapy or any&#xD;
             immunosuppressive therapy.&#xD;
&#xD;
          -  Patients who used hematopoietic colony-stimulating growth factors within 2 weeks of&#xD;
             study treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dana Farber Cancer Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The West Clinic</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wilrijk</city>
        <zip>2610</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>HUS</city>
        <zip>FIN-00029</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint Herblain cedex</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Koto ku</city>
        <state>Tokyo</state>
        <zip>135 8550</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Valencia</city>
        <state>Comunidad Valenciana</state>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chur</city>
        <zip>7000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Geneve 14</city>
        <zip>CH 1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zuerich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hong Kong</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 17, 2016</study_first_submitted>
  <study_first_submitted_qc>June 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 21, 2016</study_first_posted>
  <results_first_submitted>May 25, 2021</results_first_submitted>
  <results_first_submitted_qc>July 12, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 11, 2021</results_first_posted>
  <last_update_submitted>July 12, 2021</last_update_submitted>
  <last_update_submitted_qc>July 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Triple negative breast cancer</keyword>
  <keyword>Pancreatic carcinoma</keyword>
  <keyword>Melanoma</keyword>
  <keyword>Endometrial Carcinoma</keyword>
  <keyword>Immuno oncology</keyword>
  <keyword>Monoclonal antibody</keyword>
  <keyword>PDR001</keyword>
  <keyword>MCS110</keyword>
  <keyword>Advanced malignancies</keyword>
  <keyword>metasteses</keyword>
  <keyword>advanced cancer</keyword>
  <keyword>malignant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
    <mesh_term>Endometrial Neoplasms</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spartalizumab</mesh_term>
    <mesh_term>Sargramostim</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.&#xD;
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.</ipd_description>
    <ipd_url>https://www.clinicalstudydatarequest.com/</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 23, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/44/NCT02807844/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 29, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/44/NCT02807844/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ph Ib: MCS110 1 mg/kg Q3W + PDR001 100 mg Q3W</title>
          <description>Phase Ib: MCS110 1 mg/kg every 3 weeks (Q3W) + PDR001 100 mg Q3W</description>
        </group>
        <group group_id="P2">
          <title>Ph Ib: MCS110 3 mg/kg Q3W + PDR001 100 mg Q3W</title>
          <description>Phase Ib: MCS110 3 mg/kg Q3W + PDR001 100 mg Q3W</description>
        </group>
        <group group_id="P3">
          <title>Ph Ib: MCS110 3 mg/kg Q3W + PDR001 300 mg Q3W</title>
          <description>Phase Ib: MCS110 3 mg/kg Q3W + PDR001 300 mg Q3W</description>
        </group>
        <group group_id="P4">
          <title>Ph Ib: MCS110 5 mg/kg Q3W + PDR001 300 mg Q3W</title>
          <description>Phase Ib: MCS110 5 mg/kg Q3W + PDR001 300 mg Q3W</description>
        </group>
        <group group_id="P5">
          <title>Ph Ib: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W</title>
          <description>Phase Ib: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W</description>
        </group>
        <group group_id="P6">
          <title>Ph Ib: MCS110 10 mg/kg Q3W + PDR001 300 mg Q3W</title>
          <description>Phase Ib: MCS110 10 mg/kg Q3W + PDR001 300 mg Q3W</description>
        </group>
        <group group_id="P7">
          <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - TNBC</title>
          <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Triple negative breast cancer (TNBC)</description>
        </group>
        <group group_id="P8">
          <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - PC</title>
          <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Pancreatic cancer (PC)</description>
        </group>
        <group group_id="P9">
          <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - EC</title>
          <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Endometrial cancer (EC)</description>
        </group>
        <group group_id="P10">
          <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - ME</title>
          <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Melanoma (ME)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="13"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="11"/>
                <participants group_id="P7" count="20"/>
                <participants group_id="P8" count="20"/>
                <participants group_id="P9" count="21"/>
                <participants group_id="P10" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="13"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="11"/>
                <participants group_id="P7" count="20"/>
                <participants group_id="P8" count="20"/>
                <participants group_id="P9" count="21"/>
                <participants group_id="P10" count="20"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Progressive disease</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="8"/>
                <participants group_id="P7" count="14"/>
                <participants group_id="P8" count="17"/>
                <participants group_id="P9" count="19"/>
                <participants group_id="P10" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ph Ib: MCS110 1 mg/kg Q3W + PDR001 100 mg Q3W</title>
          <description>Phase Ib: MCS110 1 mg/kg every 3 weeks (Q3W) + PDR001 100 mg Q3W</description>
        </group>
        <group group_id="B2">
          <title>Ph Ib: MCS110 3 mg/kg Q3W + PDR001 100 mg Q3W</title>
          <description>Phase Ib: MCS110 3 mg/kg Q3W + PDR001 100 mg Q3W</description>
        </group>
        <group group_id="B3">
          <title>Ph Ib: MCS110 3 mg/kg Q3W + PDR001 300 mg Q3W</title>
          <description>Phase Ib: MCS110 3 mg/kg Q3W + PDR001 300 mg Q3W</description>
        </group>
        <group group_id="B4">
          <title>Ph Ib: MCS110 5 mg/kg Q3W + PDR001 300 mg Q3W</title>
          <description>Phase Ib: MCS110 5 mg/kg Q3W + PDR001 300 mg Q3W</description>
        </group>
        <group group_id="B5">
          <title>Ph Ib: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W</title>
          <description>Phase Ib: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W</description>
        </group>
        <group group_id="B6">
          <title>Ph Ib: MCS110 10 mg/kg Q3W + PDR001 300 mg Q3W</title>
          <description>Phase Ib: MCS110 10 mg/kg Q3W + PDR001 300 mg Q3W</description>
        </group>
        <group group_id="B7">
          <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - TNBC</title>
          <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Triple negative breast cancer (TNBC)</description>
        </group>
        <group group_id="B8">
          <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - PC</title>
          <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Pancreatic cancer (PC)</description>
        </group>
        <group group_id="B9">
          <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - EC</title>
          <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Endometrial cancer (EC)</description>
        </group>
        <group group_id="B10">
          <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - ME</title>
          <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Melanoma (ME)</description>
        </group>
        <group group_id="B11">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="12"/>
            <count group_id="B4" value="13"/>
            <count group_id="B5" value="6"/>
            <count group_id="B6" value="11"/>
            <count group_id="B7" value="20"/>
            <count group_id="B8" value="20"/>
            <count group_id="B9" value="21"/>
            <count group_id="B10" value="20"/>
            <count group_id="B11" value="141"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="8"/>
                    <measurement group_id="B7" value="20"/>
                    <measurement group_id="B8" value="11"/>
                    <measurement group_id="B9" value="9"/>
                    <measurement group_id="B10" value="12"/>
                    <measurement group_id="B11" value="95"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="9"/>
                    <measurement group_id="B9" value="12"/>
                    <measurement group_id="B10" value="8"/>
                    <measurement group_id="B11" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.3" spread="14.72"/>
                    <measurement group_id="B2" value="56.9" spread="11.13"/>
                    <measurement group_id="B3" value="59.3" spread="9.94"/>
                    <measurement group_id="B4" value="55.4" spread="10.03"/>
                    <measurement group_id="B5" value="57.3" spread="14.02"/>
                    <measurement group_id="B6" value="58.6" spread="11.13"/>
                    <measurement group_id="B7" value="50.0" spread="8.29"/>
                    <measurement group_id="B8" value="61.5" spread="11.33"/>
                    <measurement group_id="B9" value="62.8" spread="10.13"/>
                    <measurement group_id="B10" value="60.7" spread="13.15"/>
                    <measurement group_id="B11" value="58.5" spread="11.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="20"/>
                    <measurement group_id="B8" value="8"/>
                    <measurement group_id="B9" value="21"/>
                    <measurement group_id="B10" value="9"/>
                    <measurement group_id="B11" value="96"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="12"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="11"/>
                    <measurement group_id="B11" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="5"/>
                    <measurement group_id="B8" value="4"/>
                    <measurement group_id="B9" value="4"/>
                    <measurement group_id="B10" value="7"/>
                    <measurement group_id="B11" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="9"/>
                    <measurement group_id="B7" value="14"/>
                    <measurement group_id="B8" value="14"/>
                    <measurement group_id="B9" value="14"/>
                    <measurement group_id="B10" value="12"/>
                    <measurement group_id="B11" value="106"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="2"/>
                    <measurement group_id="B10" value="1"/>
                    <measurement group_id="B11" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Phase Ib: Percentage of Participants With Adverse Events, as a Measure of Safety</title>
        <description>Phase Ib: To characterize the safety and tolerability of MCS110 in combination with PDR001 in patients with advanced solid malignancies and to identify a recommended dose combination for Phase II.</description>
        <time_frame>From start of treatment to a maximum timeframe of 116.4 weeks for phase Ib</time_frame>
        <population>Safety Analysis Set. A statistical analysis for this endpoint was not performed since it is not clinically relevant.</population>
        <group_list>
          <group group_id="O1">
            <title>Ph Ib: MCS110 1 mg/kg Q3W + PDR001 100 mg Q3W</title>
            <description>Phase Ib: MCS110 1 mg/kg every 3 weeks (Q3W) + PDR001 100 mg Q3W</description>
          </group>
          <group group_id="O2">
            <title>Ph Ib: MCS110 3 mg/kg Q3W + PDR001 100 mg Q3W</title>
            <description>Phase Ib: MCS110 3 mg/kg Q3W + PDR001 100 mg Q3W</description>
          </group>
          <group group_id="O3">
            <title>Ph Ib: MCS110 3 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 3 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O4">
            <title>Ph Ib: MCS110 5 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 5 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O5">
            <title>Ph Ib: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O6">
            <title>Ph Ib: MCS110 10 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 10 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
        </group_list>
        <measure>
          <title>Phase Ib: Percentage of Participants With Adverse Events, as a Measure of Safety</title>
          <description>Phase Ib: To characterize the safety and tolerability of MCS110 in combination with PDR001 in patients with advanced solid malignancies and to identify a recommended dose combination for Phase II.</description>
          <population>Safety Analysis Set. A statistical analysis for this endpoint was not performed since it is not clinically relevant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Adverse events (AEs) - all grades</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="13"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adverse events - Treatment-related - all grades</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious Adverse Events (SAEs) - all grades</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs - Treatment-related - all grades</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatal SAEs - all grades</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatal SAEs - Treatment-related - all grades</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs leading to discontinuation - all grades</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs leading to discontinuation - Treatment-related - all grades</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs leading to dose adjustment / interruption - all grades</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs requiring additional therapy - all grades</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Phase II : Overall Response Rate (ORR) - Per RECIST v1.1</title>
        <description>Overall Response Rate (ORR) is defined as the proportion of patients with a best overall response assessed by CT scan or MRI of complete response (CR), disappearance of all measurable and non-measurable lesions or partial response (PR), at least a 30% decrease in the sum of diameter of all measurable lesions, taking as reference the baseline sum of diameters,. based on local Investigator assessment, as per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1)</description>
        <time_frame>4 years</time_frame>
        <population>Full Analysis Set. A statistical analysis for this endpoint was not performed since it is not clinically relevant.</population>
        <group_list>
          <group group_id="O1">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - TNBC</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Triple negative breast cancer (TNBC)</description>
          </group>
          <group group_id="O2">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - PC</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Pancreatic cancer (PC)</description>
          </group>
          <group group_id="O3">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - EC</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Endometrial cancer (EC)</description>
          </group>
          <group group_id="O4">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - ME</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Melanoma (ME)</description>
          </group>
        </group_list>
        <measure>
          <title>Phase II : Overall Response Rate (ORR) - Per RECIST v1.1</title>
          <description>Overall Response Rate (ORR) is defined as the proportion of patients with a best overall response assessed by CT scan or MRI of complete response (CR), disappearance of all measurable and non-measurable lesions or partial response (PR), at least a 30% decrease in the sum of diameter of all measurable lesions, taking as reference the baseline sum of diameters,. based on local Investigator assessment, as per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1)</description>
          <population>Full Analysis Set. A statistical analysis for this endpoint was not performed since it is not clinically relevant.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="0.3" upper_limit="21.6"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="13.9"/>
                    <measurement group_id="O3" value="9.5" lower_limit="1.7" upper_limit="27.1"/>
                    <measurement group_id="O4" value="0" lower_limit="0.0" upper_limit="13.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Phase II : Bayesian Inference of Overall Response Rate (ORR) - Per RECIST v1.1 - Mean</title>
        <description>Overall Response Rate (ORR) is defined as the proportion of patients with a best overall response assessed by CT scan or MRI of complete response (CR), disappearance of all measurable and non-measurable lesions or partial response (PR), at least a 30% decrease in the sum of diameter of all measurable lesions, taking as reference the baseline sum of diameters,. based on local Investigator assessment, as per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) - mean (FAS)</description>
        <time_frame>4 years</time_frame>
        <population>Full Analysis Set. Since objective responses are rare in advanced pancreatic cancer and that long lasting stable disease is considered beneficial to patients, clinical benefit rate (confirmed objective response or SD&gt;4 months) was used as the primary endpoint for antitumor activity in this study changed from objective response to for this patient population.</population>
        <group_list>
          <group group_id="O1">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - TNBC</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Triple negative breast cancer (TNBC)</description>
          </group>
          <group group_id="O2">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - PC</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Pancreatic cancer (PC)</description>
          </group>
          <group group_id="O3">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - EC</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Endometrial cancer (EC)</description>
          </group>
          <group group_id="O4">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - ME</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Melanoma (ME)</description>
          </group>
        </group_list>
        <measure>
          <title>Phase II : Bayesian Inference of Overall Response Rate (ORR) - Per RECIST v1.1 - Mean</title>
          <description>Overall Response Rate (ORR) is defined as the proportion of patients with a best overall response assessed by CT scan or MRI of complete response (CR), disappearance of all measurable and non-measurable lesions or partial response (PR), at least a 30% decrease in the sum of diameter of all measurable lesions, taking as reference the baseline sum of diameters,. based on local Investigator assessment, as per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) - mean (FAS)</description>
          <population>Full Analysis Set. Since objective responses are rare in advanced pancreatic cancer and that long lasting stable disease is considered beneficial to patients, clinical benefit rate (confirmed objective response or SD&gt;4 months) was used as the primary endpoint for antitumor activity in this study changed from objective response to for this patient population.</population>
          <units>Percentage of participants</units>
          <param>Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7" lower_limit="0.8" upper_limit="17.1"/>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Bayesian inference of Clinical Benefit Rate was measured for this arm instead - see Bayesian inference of Clinical Benefit Rate - per RECIST v1.1- mean results</measurement>
                    <measurement group_id="O3" value="10.8" lower_limit="2.6" upper_limit="23.1"/>
                    <measurement group_id="O4" value="0.8" lower_limit="0" upper_limit="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Phase II: Clinical Benefit Rate (Complete Response (CR) or Partial Response (PR) or Stable Disease (SD) &gt; 4 Month)) - Per RECIST v1.1</title>
        <description>Phase II: Clinical Benefit Rate (Complete response (CR) or Partial response (PR) or Stable disease (SD) &gt; 4 month)) per investigator based on Response evaluation criteria in solid tumors (RECIST) v1.1</description>
        <time_frame>4 years</time_frame>
        <population>Full Analysis Set. A statistical analysis for this endpoint was not performed since it is not clinically relevant.</population>
        <group_list>
          <group group_id="O1">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - TNBC</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Triple negative breast cancer (TNBC)</description>
          </group>
          <group group_id="O2">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - PC</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Pancreatic cancer (PC)</description>
          </group>
          <group group_id="O3">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - EC</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Endometrial cancer (EC)</description>
          </group>
          <group group_id="O4">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - ME</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Melanoma (ME)</description>
          </group>
        </group_list>
        <measure>
          <title>Phase II: Clinical Benefit Rate (Complete Response (CR) or Partial Response (PR) or Stable Disease (SD) &gt; 4 Month)) - Per RECIST v1.1</title>
          <description>Phase II: Clinical Benefit Rate (Complete response (CR) or Partial response (PR) or Stable disease (SD) &gt; 4 month)) per investigator based on Response evaluation criteria in solid tumors (RECIST) v1.1</description>
          <population>Full Analysis Set. A statistical analysis for this endpoint was not performed since it is not clinically relevant.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20" lower_limit="7.1" upper_limit="40.1"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="13.9"/>
                    <measurement group_id="O3" value="9.5" lower_limit="1.7" upper_limit="27.1"/>
                    <measurement group_id="O4" value="10.0" lower_limit="1.8" upper_limit="28.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Phase II: Bayesian Inference of Clinical Benefit Rate - Per RECIST v1.1- Mean</title>
        <description>Phase II: Clinical Benefit Rate (Complete response (CR) or Partial response (PR) or Stable disease (SD) &gt; 4 month)) per investigator based on Response evaluation criteria in solid tumors (RECIST) v1.1</description>
        <time_frame>4 years</time_frame>
        <population>Full Analysis Set. Since objective responses are rare in advanced pancreatic cancer and that long lasting stable disease is considered beneficial to patients, clinical benefit rate (confirmed objective response or SD&gt;4 months) was used as the primary endpoint for antitumor activity in this study changed from objective response to for this patient population.</population>
        <group_list>
          <group group_id="O1">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - TNBC</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Triple negative breast cancer (TNBC)</description>
          </group>
          <group group_id="O2">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - PC</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Pancreatic cancer (PC)</description>
          </group>
          <group group_id="O3">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - EC</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Endometrial cancer (EC)</description>
          </group>
          <group group_id="O4">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - ME</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Melanoma (ME)</description>
          </group>
        </group_list>
        <measure>
          <title>Phase II: Bayesian Inference of Clinical Benefit Rate - Per RECIST v1.1- Mean</title>
          <description>Phase II: Clinical Benefit Rate (Complete response (CR) or Partial response (PR) or Stable disease (SD) &gt; 4 month)) per investigator based on Response evaluation criteria in solid tumors (RECIST) v1.1</description>
          <population>Full Analysis Set. Since objective responses are rare in advanced pancreatic cancer and that long lasting stable disease is considered beneficial to patients, clinical benefit rate (confirmed objective response or SD&gt;4 months) was used as the primary endpoint for antitumor activity in this study changed from objective response to for this patient population.</population>
          <units>Percentage of participants</units>
          <param>Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Bayesian inference of Overall Response Rate was measured for this arm instead. See the Bayesian inference of Overall Response rate - per RECIST v1.1 - mean results</measurement>
                    <measurement group_id="O2" value="0.8" lower_limit="0" upper_limit="4.5"/>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">Bayesian inference of Overall Response Rate was measured for this arm instead. See the Bayesian inference of Overall Response rate - per RECIST v1.1 - mean results</measurement>
                    <measurement group_id="O4" value="NA" lower_limit="NA" upper_limit="NA">Bayesian inference of Overall Response Rate was measured for this arm instead. See the Bayesian inference of Overall Response rate - per RECIST v1.1 - mean results</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Phase Ib: Planned Dose Intensity - MCS110</title>
        <description>To characterize the tolerability of MCS110 given in combination with PDR001 and to identify a recommended dose combination for Phase II. Planned dose intensity for MCS110 is cumulative planned dose (mg/kg)/ number of doses scheduled per protocol during treatment period (i.e., this is equivalent to planned dose level).</description>
        <time_frame>Measured up to a max of 112.4 weeks</time_frame>
        <population>Safety Set. A statistical analysis for this endpoint was not performed since it is not clinically relevant.</population>
        <group_list>
          <group group_id="O1">
            <title>Ph Ib: MCS110 1 mg/kg Q3W + PDR001 100 mg Q3W</title>
            <description>Phase Ib: MCS110 1 mg/kg every 3 weeks (Q3W) + PDR001 100 mg Q3W</description>
          </group>
          <group group_id="O2">
            <title>Ph Ib: MCS110 3 mg/kg Q3W + PDR001 100 mg Q3W</title>
            <description>Phase Ib: MCS110 3 mg/kg Q3W + PDR001 100 mg Q3W</description>
          </group>
          <group group_id="O3">
            <title>Ph Ib: MCS110 3 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 3 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O4">
            <title>Ph Ib: MCS110 5 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 5 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O5">
            <title>Ph Ib: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O6">
            <title>Ph Ib: MCS110 10 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 10 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
        </group_list>
        <measure>
          <title>Phase Ib: Planned Dose Intensity - MCS110</title>
          <description>To characterize the tolerability of MCS110 given in combination with PDR001 and to identify a recommended dose combination for Phase II. Planned dose intensity for MCS110 is cumulative planned dose (mg/kg)/ number of doses scheduled per protocol during treatment period (i.e., this is equivalent to planned dose level).</description>
          <population>Safety Set. A statistical analysis for this endpoint was not performed since it is not clinically relevant.</population>
          <units>mg/kg/3wks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.86" spread="0.191"/>
                    <measurement group_id="O2" value="2.74" spread="0.386"/>
                    <measurement group_id="O3" value="2.66" spread="0.435"/>
                    <measurement group_id="O4" value="4.85" spread="0.286"/>
                    <measurement group_id="O5" value="7.05" spread="0.594"/>
                    <measurement group_id="O6" value="9.47" spread="1.093"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Phase Ib: Relative Dose Intensity - MCS110</title>
        <description>To characterize the tolerability of MCS110 given in combination with PDR001 and to identify a recommended dose combination for Phase II. Relative dose intensity (%) is 100 × dose intensity (mg/kg/3wks)/planned dose intensity (mg/kg/3wks).</description>
        <time_frame>Measured up to a max of 112.4 weeks</time_frame>
        <population>Safety Set. A statistical analysis for this endpoint was not performed since it is not clinically relevant.</population>
        <group_list>
          <group group_id="O1">
            <title>Ph Ib: MCS110 1 mg/kg Q3W + PDR001 100 mg Q3W</title>
            <description>Phase Ib: MCS110 1 mg/kg every 3 weeks (Q3W) + PDR001 100 mg Q3W</description>
          </group>
          <group group_id="O2">
            <title>Ph Ib: MCS110 3 mg/kg Q3W + PDR001 100 mg Q3W</title>
            <description>Phase Ib: MCS110 3 mg/kg Q3W + PDR001 100 mg Q3W</description>
          </group>
          <group group_id="O3">
            <title>Ph Ib: MCS110 3 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 3 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O4">
            <title>Ph Ib: MCS110 5 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 5 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O5">
            <title>Ph Ib: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O6">
            <title>Ph Ib: MCS110 10 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 10 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
        </group_list>
        <measure>
          <title>Phase Ib: Relative Dose Intensity - MCS110</title>
          <description>To characterize the tolerability of MCS110 given in combination with PDR001 and to identify a recommended dose combination for Phase II. Relative dose intensity (%) is 100 × dose intensity (mg/kg/3wks)/planned dose intensity (mg/kg/3wks).</description>
          <population>Safety Set. A statistical analysis for this endpoint was not performed since it is not clinically relevant.</population>
          <units>Percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" spread="100"/>
                    <measurement group_id="O2" value="100" spread="100"/>
                    <measurement group_id="O3" value="100" spread="100"/>
                    <measurement group_id="O4" value="99.23" spread="2.774"/>
                    <measurement group_id="O5" value="100" spread="100"/>
                    <measurement group_id="O6" value="100" spread="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Phase Ib: Planned Dose Intensity - PDR001</title>
        <description>To characterize the tolerability of MCS110 given in combination with PDR001 and to identify a recommended dose combination for Phase II. Planned dose intensity for PDR001 (mg/3wks) is planned cumulative dose (mg)/ number of doses scheduled per protocol during treatment period (i.e., this is equivalent to planned dose level).</description>
        <time_frame>Measured up to a max of 112.4 weeks</time_frame>
        <population>Safety Set. A statistical analysis for this endpoint was not performed since it is not clinically relevant.</population>
        <group_list>
          <group group_id="O1">
            <title>Ph Ib: MCS110 1 mg/kg Q3W + PDR001 100 mg Q3W</title>
            <description>Phase Ib: MCS110 1 mg/kg every 3 weeks (Q3W) + PDR001 100 mg Q3W</description>
          </group>
          <group group_id="O2">
            <title>Ph Ib: MCS110 3 mg/kg Q3W + PDR001 100 mg Q3W</title>
            <description>Phase Ib: MCS110 3 mg/kg Q3W + PDR001 100 mg Q3W</description>
          </group>
          <group group_id="O3">
            <title>Ph Ib: MCS110 3 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 3 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O4">
            <title>Ph Ib: MCS110 5 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 5 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O5">
            <title>Ph Ib: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O6">
            <title>Ph Ib: MCS110 10 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 10 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
        </group_list>
        <measure>
          <title>Phase Ib: Planned Dose Intensity - PDR001</title>
          <description>To characterize the tolerability of MCS110 given in combination with PDR001 and to identify a recommended dose combination for Phase II. Planned dose intensity for PDR001 (mg/3wks) is planned cumulative dose (mg)/ number of doses scheduled per protocol during treatment period (i.e., this is equivalent to planned dose level).</description>
          <population>Safety Set. A statistical analysis for this endpoint was not performed since it is not clinically relevant.</population>
          <units>mg/3wks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.09" spread="19.058"/>
                    <measurement group_id="O2" value="91.18" spread="12.873"/>
                    <measurement group_id="O3" value="265.83" spread="43.528"/>
                    <measurement group_id="O4" value="293.59" spread="16.013"/>
                    <measurement group_id="O5" value="282.12" spread="23.773"/>
                    <measurement group_id="O6" value="289.04" spread="20.329"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Phase Ib: Relative Dose Intensity - PDR001</title>
        <description>To characterize the tolerability of MCS110 given in combination with PDR001 and to identify a recommended dose combination for Phase II. Relative dose intensity (%) is 100 × dose intensity (mg/3wks)/planned dose intensity (mg/3wks).</description>
        <time_frame>Measured up to a max of 112.4 weeks</time_frame>
        <population>Safety Set. A statistical analysis for this endpoint was not performed since it is not clinically relevant.</population>
        <group_list>
          <group group_id="O1">
            <title>Ph Ib: MCS110 1 mg/kg Q3W + PDR001 100 mg Q3W</title>
            <description>Phase Ib: MCS110 1 mg/kg every 3 weeks (Q3W) + PDR001 100 mg Q3W</description>
          </group>
          <group group_id="O2">
            <title>Ph Ib: MCS110 3 mg/kg Q3W + PDR001 100 mg Q3W</title>
            <description>Phase Ib: MCS110 3 mg/kg Q3W + PDR001 100 mg Q3W</description>
          </group>
          <group group_id="O3">
            <title>Ph Ib: MCS110 3 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 3 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O4">
            <title>Ph Ib: MCS110 5 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 5 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O5">
            <title>Ph Ib: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O6">
            <title>Ph Ib: MCS110 10 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 10 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
        </group_list>
        <measure>
          <title>Phase Ib: Relative Dose Intensity - PDR001</title>
          <description>To characterize the tolerability of MCS110 given in combination with PDR001 and to identify a recommended dose combination for Phase II. Relative dose intensity (%) is 100 × dose intensity (mg/3wks)/planned dose intensity (mg/3wks).</description>
          <population>Safety Set. A statistical analysis for this endpoint was not performed since it is not clinically relevant.</population>
          <units>Percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.00" spread="100.00"/>
                    <measurement group_id="O2" value="100.00" spread="100.00"/>
                    <measurement group_id="O3" value="100.00" spread="100.00"/>
                    <measurement group_id="O4" value="100.00" spread="100.00"/>
                    <measurement group_id="O5" value="100.00" spread="100.00"/>
                    <measurement group_id="O6" value="100.00" spread="100.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Phase Ib: Number of Participants With Dose Reductions</title>
        <description>To characterize the tolerability of MCS110 given in combination with PDR001 and to identify a recommended dose combination for Phase II.</description>
        <time_frame>Measured up to a max of 112.4 weeks</time_frame>
        <population>Safety Set. A statistical analysis for this endpoint was not performed since it is not clinically relevant.</population>
        <group_list>
          <group group_id="O1">
            <title>Ph Ib: MCS110 1 mg/kg Q3W + PDR001 100 mg Q3W</title>
            <description>Phase Ib: MCS110 1 mg/kg every 3 weeks (Q3W) + PDR001 100 mg Q3W</description>
          </group>
          <group group_id="O2">
            <title>Ph Ib: MCS110 3 mg/kg Q3W + PDR001 100 mg Q3W</title>
            <description>Phase Ib: MCS110 3 mg/kg Q3W + PDR001 100 mg Q3W</description>
          </group>
          <group group_id="O3">
            <title>Ph Ib: MCS110 3 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 3 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O4">
            <title>Ph Ib: MCS110 5 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 5 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O5">
            <title>Ph Ib: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O6">
            <title>Ph Ib: MCS110 10 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 10 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
        </group_list>
        <measure>
          <title>Phase Ib: Number of Participants With Dose Reductions</title>
          <description>To characterize the tolerability of MCS110 given in combination with PDR001 and to identify a recommended dose combination for Phase II.</description>
          <population>Safety Set. A statistical analysis for this endpoint was not performed since it is not clinically relevant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>n (%) of participants with no dose reduction- Study drug: MCS110</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="13"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>n (%) of participants with no dose reduction- Study drug: PDR001</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="13"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Phase Ib: Number of Dose Interruptions Per Participant</title>
        <description>To characterize the tolerability of MCS110 given in combination with PDR001 and to identify a recommended dose combination for Phase II.</description>
        <time_frame>Measured up to a max of 112.4 weeks</time_frame>
        <population>Safety Set. A statistical analysis for this endpoint was not performed since it is not clinically relevant.</population>
        <group_list>
          <group group_id="O1">
            <title>Ph Ib: MCS110 1 mg/kg Q3W + PDR001 100 mg Q3W</title>
            <description>Phase Ib: MCS110 1 mg/kg every 3 weeks (Q3W) + PDR001 100 mg Q3W</description>
          </group>
          <group group_id="O2">
            <title>Ph Ib: MCS110 3 mg/kg Q3W + PDR001 100 mg Q3W</title>
            <description>Phase Ib: MCS110 3 mg/kg Q3W + PDR001 100 mg Q3W</description>
          </group>
          <group group_id="O3">
            <title>Ph Ib: MCS110 3 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 3 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O4">
            <title>Ph Ib: MCS110 5 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 5 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O5">
            <title>Ph Ib: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O6">
            <title>Ph Ib: MCS110 10 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 10 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
        </group_list>
        <measure>
          <title>Phase Ib: Number of Dose Interruptions Per Participant</title>
          <description>To characterize the tolerability of MCS110 given in combination with PDR001 and to identify a recommended dose combination for Phase II.</description>
          <population>Safety Set. A statistical analysis for this endpoint was not performed since it is not clinically relevant.</population>
          <units>Dose interruptions per participant</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of dose interruptions per subject - Study drug: MCS110</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="1.97"/>
                    <measurement group_id="O2" value="0.3" spread="0.45"/>
                    <measurement group_id="O3" value="0.3" spread="0.45"/>
                    <measurement group_id="O4" value="0.0" spread="0.0"/>
                    <measurement group_id="O5" value="0.3" spread="0.52"/>
                    <measurement group_id="O6" value="0.1" spread="0.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of dose interruptions per subject - Study drug: PDR001</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="1.97"/>
                    <measurement group_id="O2" value="0.3" spread="0.45"/>
                    <measurement group_id="O3" value="0.3" spread="0.45"/>
                    <measurement group_id="O4" value="0.0" spread="0.0"/>
                    <measurement group_id="O5" value="0.3" spread="0.52"/>
                    <measurement group_id="O6" value="0.1" spread="0.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Phase Ib: Number of Subjects With at Least One Dose Interruption</title>
        <description>To characterize the tolerability of MCS110 given in combination with PDR001 and to identify a recommended dose combination for Phase II.</description>
        <time_frame>Measured up to a max of 112.4 weeks</time_frame>
        <population>Safety Set. A statistical analysis for this endpoint was not performed since it is not clinically relevant.</population>
        <group_list>
          <group group_id="O1">
            <title>Ph Ib: MCS110 1 mg/kg Q3W + PDR001 100 mg Q3W</title>
            <description>Phase Ib: MCS110 1 mg/kg every 3 weeks (Q3W) + PDR001 100 mg Q3W</description>
          </group>
          <group group_id="O2">
            <title>Ph Ib: MCS110 3 mg/kg Q3W + PDR001 100 mg Q3W</title>
            <description>Phase Ib: MCS110 3 mg/kg Q3W + PDR001 100 mg Q3W</description>
          </group>
          <group group_id="O3">
            <title>Ph Ib: MCS110 3 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 3 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O4">
            <title>Ph Ib: MCS110 5 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 5 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O5">
            <title>Ph Ib: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O6">
            <title>Ph Ib: MCS110 10 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 10 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
        </group_list>
        <measure>
          <title>Phase Ib: Number of Subjects With at Least One Dose Interruption</title>
          <description>To characterize the tolerability of MCS110 given in combination with PDR001 and to identify a recommended dose combination for Phase II.</description>
          <population>Safety Set. A statistical analysis for this endpoint was not performed since it is not clinically relevant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of subjects with at least one dose interruption - by reason - Adverse Event - MCS110</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of subjects with at least one dose interruption - by reason - Adverse Event - PDR001</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Phase Ib: Number of Participants With Dose Limiting Toxicities (DLTs) During the First 2 Cycles of Study Treatment</title>
        <description>Phase Ib: Dose limiting toxicities occurring during the first 2 cycles by system organ class, preferred term and maximum grade for Phase Ib. The National Cancer Institute Common Terminology Criteria for Adverse events (NCI CTCAE) version 4.03 was used for all grading.</description>
        <time_frame>the first 2 cycles of study treatment; cycle = 21 days (i.e., at day 42)</time_frame>
        <population>Dose Determination Set (DDS). A statistical analysis for this endpoint was not performed since it is not clinically relevant.</population>
        <group_list>
          <group group_id="O1">
            <title>Ph Ib: MCS110 1 mg/kg Q3W + PDR001 100 mg Q3W</title>
            <description>Phase Ib: MCS110 1 mg/kg every 3 weeks (Q3W) + PDR001 100 mg Q3W</description>
          </group>
          <group group_id="O2">
            <title>Ph Ib: MCS110 3 mg/kg Q3W + PDR001 100 mg Q3W</title>
            <description>Phase Ib: MCS110 3 mg/kg Q3W + PDR001 100 mg Q3W</description>
          </group>
          <group group_id="O3">
            <title>Ph Ib: MCS110 3 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 3 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O4">
            <title>Ph Ib: MCS110 5 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 5 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O5">
            <title>Ph Ib: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O6">
            <title>Ph Ib: MCS110 10 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 10 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
        </group_list>
        <measure>
          <title>Phase Ib: Number of Participants With Dose Limiting Toxicities (DLTs) During the First 2 Cycles of Study Treatment</title>
          <description>Phase Ib: Dose limiting toxicities occurring during the first 2 cycles by system organ class, preferred term and maximum grade for Phase Ib. The National Cancer Institute Common Terminology Criteria for Adverse events (NCI CTCAE) version 4.03 was used for all grading.</description>
          <population>Dose Determination Set (DDS). A statistical analysis for this endpoint was not performed since it is not clinically relevant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>n (%) of subjects with at least one event - all grades</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>n (%) Investigations - all grades</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>n (%) Blood creatine phosphokinase increased - all grades</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase II : Overall Response Rate (ORR) - Per irRC</title>
        <description>Phase II: Overall Response Rate (Complete response (CR) or Partial response (PR)) (with confirmation) as per investigator based on immune related Response criteria (irRC) (FAS)</description>
        <time_frame>4 years</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - TNBC</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Triple negative breast cancer (TNBC)</description>
          </group>
          <group group_id="O2">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - PC</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Pancreatic cancer (PC)</description>
          </group>
          <group group_id="O3">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - EC</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Endometrial cancer (EC)</description>
          </group>
          <group group_id="O4">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - ME</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Melanoma (ME)</description>
          </group>
        </group_list>
        <measure>
          <title>Phase II : Overall Response Rate (ORR) - Per irRC</title>
          <description>Phase II: Overall Response Rate (Complete response (CR) or Partial response (PR)) (with confirmation) as per investigator based on immune related Response criteria (irRC) (FAS)</description>
          <population>Full Analysis Set</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="0.3" upper_limit="21.6"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="13.9"/>
                    <measurement group_id="O3" value="9.5" lower_limit="1.7" upper_limit="27.1"/>
                    <measurement group_id="O4" value="0" lower_limit="0.0" upper_limit="13.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase Ib: Overall Response Rate (ORR)</title>
        <description>Phase Ib: Overall Response Rate (Complete response (CR) or Partial response (PR)), per RECIST v1.1 and per immune related Response criteria (irRC)</description>
        <time_frame>4 years</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Ph Ib: MCS110 1 mg/kg Q3W + PDR001 100 mg Q3W</title>
            <description>Phase Ib: MCS110 1 mg/kg every 3 weeks (Q3W) + PDR001 100 mg Q3W</description>
          </group>
          <group group_id="O2">
            <title>Ph Ib: MCS110 3 mg/kg Q3W + PDR001 100 mg Q3W</title>
            <description>Phase Ib: MCS110 3 mg/kg Q3W + PDR001 100 mg Q3W</description>
          </group>
          <group group_id="O3">
            <title>Ph Ib: MCS110 3 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 3 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O4">
            <title>Ph Ib: MCS110 5 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 5 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O5">
            <title>Ph Ib: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O6">
            <title>Ph Ib: MCS110 10 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 10 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
        </group_list>
        <measure>
          <title>Phase Ib: Overall Response Rate (ORR)</title>
          <description>Phase Ib: Overall Response Rate (Complete response (CR) or Partial response (PR)), per RECIST v1.1 and per immune related Response criteria (irRC)</description>
          <population>Full Analysis Set</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall Response Rate as per investigator based on RECIST v1.1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7" lower_limit="0.9" upper_limit="58.2"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="22.1"/>
                    <measurement group_id="O3" value="0" lower_limit="0.0" upper_limit="22.1"/>
                    <measurement group_id="O4" value="0" lower_limit="0.0" upper_limit="20.6"/>
                    <measurement group_id="O5" value="0" lower_limit="0.0" upper_limit="39.3"/>
                    <measurement group_id="O6" value="9.1" lower_limit="0.5" upper_limit="36.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall Response Rate - as per investigator based on irRC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7" lower_limit="0.9" upper_limit="58.2"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="22.1"/>
                    <measurement group_id="O3" value="0" lower_limit="0.0" upper_limit="22.1"/>
                    <measurement group_id="O4" value="0" lower_limit="0.0" upper_limit="20.6"/>
                    <measurement group_id="O5" value="0" lower_limit="0.0" upper_limit="39.3"/>
                    <measurement group_id="O6" value="9.1" lower_limit="0.5" upper_limit="36.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase II : Bayesian Inference of Overall Response Rate (ORR) - Per irRC - Mean</title>
        <description>Phase II: Overall Response Rate (Complete response (CR) or Partial response (PR)) (with confirmation) as per investigator based on immune related Response criteria (irRC)- mean (FAS)</description>
        <time_frame>4 years</time_frame>
        <population>Full Analysis Set. Since objective responses are rare in advanced pancreatic cancer and that long lasting stable disease is considered beneficial to patients, clinical benefit rate (confirmed objective response or SD&gt;4 months) was used as the primary endpoint for antitumor activity in this study changed from objective response to for this patient population.</population>
        <group_list>
          <group group_id="O1">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - TNBC</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Triple negative breast cancer (TNBC)</description>
          </group>
          <group group_id="O2">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - PC</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Pancreatic cancer (PC)</description>
          </group>
          <group group_id="O3">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - EC</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Endometrial cancer (EC)</description>
          </group>
          <group group_id="O4">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - ME</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Melanoma (ME)</description>
          </group>
        </group_list>
        <measure>
          <title>Phase II : Bayesian Inference of Overall Response Rate (ORR) - Per irRC - Mean</title>
          <description>Phase II: Overall Response Rate (Complete response (CR) or Partial response (PR)) (with confirmation) as per investigator based on immune related Response criteria (irRC)- mean (FAS)</description>
          <population>Full Analysis Set. Since objective responses are rare in advanced pancreatic cancer and that long lasting stable disease is considered beneficial to patients, clinical benefit rate (confirmed objective response or SD&gt;4 months) was used as the primary endpoint for antitumor activity in this study changed from objective response to for this patient population.</population>
          <units>Percentage of participants</units>
          <param>Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7" lower_limit="0.8" upper_limit="17.1"/>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Bayesian inference of Clinical Benefit Rate was measured for this arm instead - see Bayesian inference of Clinical Benefit Rate - per irRC - mean results</measurement>
                    <measurement group_id="O3" value="10.8" lower_limit="2.6" upper_limit="23.1"/>
                    <measurement group_id="O4" value="0.8" lower_limit="0" upper_limit="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 1b: Clinical Benefit Rate (CBR)</title>
        <description>Phase 1b: Clinical Benefit Rate (Complete response (CR) or Partial response (PR) or Stable disease (SD) &gt; 4 month)) per RECIST v1.1 and per immune related Response criteria (irRC)</description>
        <time_frame>4 years</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Ph Ib: MCS110 1 mg/kg Q3W + PDR001 100 mg Q3W</title>
            <description>Phase Ib: MCS110 1 mg/kg every 3 weeks (Q3W) + PDR001 100 mg Q3W</description>
          </group>
          <group group_id="O2">
            <title>Ph Ib: MCS110 3 mg/kg Q3W + PDR001 100 mg Q3W</title>
            <description>Phase Ib: MCS110 3 mg/kg Q3W + PDR001 100 mg Q3W</description>
          </group>
          <group group_id="O3">
            <title>Ph Ib: MCS110 3 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 3 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O4">
            <title>Ph Ib: MCS110 5 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 5 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O5">
            <title>Ph Ib: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O6">
            <title>Ph Ib: MCS110 10 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 10 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 1b: Clinical Benefit Rate (CBR)</title>
          <description>Phase 1b: Clinical Benefit Rate (Complete response (CR) or Partial response (PR) or Stable disease (SD) &gt; 4 month)) per RECIST v1.1 and per immune related Response criteria (irRC)</description>
          <population>Full Analysis Set</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Clinical Benefit Rate - as per investigator based on RECIST v1.1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3" lower_limit="6.3" upper_limit="72.9"/>
                    <measurement group_id="O2" value="8.3" lower_limit="0.4" upper_limit="33.9"/>
                    <measurement group_id="O3" value="0" lower_limit="0.0" upper_limit="22.1"/>
                    <measurement group_id="O4" value="0" lower_limit="0.0" upper_limit="20.6"/>
                    <measurement group_id="O5" value="0" lower_limit="0.0" upper_limit="39.3"/>
                    <measurement group_id="O6" value="18.2" lower_limit="3.3" upper_limit="47.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clinical Benefit Rate - as per investigator based on irRC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0" lower_limit="15.3" upper_limit="84.7"/>
                    <measurement group_id="O2" value="8.3" lower_limit="0.4" upper_limit="33.9"/>
                    <measurement group_id="O3" value="0" lower_limit="0.0" upper_limit="22.1"/>
                    <measurement group_id="O4" value="7.7" lower_limit="0.4" upper_limit="31.6"/>
                    <measurement group_id="O5" value="33.3" lower_limit="6.3" upper_limit="72.9"/>
                    <measurement group_id="O6" value="18.2" lower_limit="3.3" upper_limit="47.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase II: Clinical Benefit Rate (Complete Response (CR) or Partial Response (PR) or Stable Disease (SD) &gt; 4 Month)) - Per irRC</title>
        <description>Phase II: Clinical Benefit Rate (Complete response (CR) or Partial response (PR) or Stable disease (SD) &gt; 4 month)) per immune related Response criteria (irRC)</description>
        <time_frame>4 years</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - TNBC</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Triple negative breast cancer (TNBC)</description>
          </group>
          <group group_id="O2">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - PC</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Pancreatic cancer (PC)</description>
          </group>
          <group group_id="O3">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - EC</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Endometrial cancer (EC)</description>
          </group>
          <group group_id="O4">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - ME</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Melanoma (ME)</description>
          </group>
        </group_list>
        <measure>
          <title>Phase II: Clinical Benefit Rate (Complete Response (CR) or Partial Response (PR) or Stable Disease (SD) &gt; 4 Month)) - Per irRC</title>
          <description>Phase II: Clinical Benefit Rate (Complete response (CR) or Partial response (PR) or Stable disease (SD) &gt; 4 month)) per immune related Response criteria (irRC)</description>
          <population>Full Analysis Set</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0" lower_limit="7.1" upper_limit="40.1"/>
                    <measurement group_id="O2" value="5.0" lower_limit="0.3" upper_limit="21.6"/>
                    <measurement group_id="O3" value="19.0" lower_limit="6.8" upper_limit="38.4"/>
                    <measurement group_id="O4" value="30.0" lower_limit="14.0" upper_limit="50.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase II: Bayesian Inference of Clinical Benefit Rate - Per irRC - Mean</title>
        <description>Phase II: Clinical Benefit Rate (Complete response (CR) or Partial response (PR) or Stable disease (SD) &gt; 4 month)) per investigator based on immune related Response criteria (irRC)- mean (FAS)</description>
        <time_frame>4 years</time_frame>
        <population>Full Analysis Set. Since objective responses are rare in advanced pancreatic cancer and that long lasting stable disease is considered beneficial to patients, clinical benefit rate (confirmed objective response or SD&gt;4 months) was used as the primary endpoint for antitumor activity in this study changed from objective response to for this patient population.</population>
        <group_list>
          <group group_id="O1">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - TNBC</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Triple negative breast cancer (TNBC)</description>
          </group>
          <group group_id="O2">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - PC</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Pancreatic cancer (PC)</description>
          </group>
          <group group_id="O3">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - EC</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Endometrial cancer (EC)</description>
          </group>
          <group group_id="O4">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - ME</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Melanoma (ME)</description>
          </group>
        </group_list>
        <measure>
          <title>Phase II: Bayesian Inference of Clinical Benefit Rate - Per irRC - Mean</title>
          <description>Phase II: Clinical Benefit Rate (Complete response (CR) or Partial response (PR) or Stable disease (SD) &gt; 4 month)) per investigator based on immune related Response criteria (irRC)- mean (FAS)</description>
          <population>Full Analysis Set. Since objective responses are rare in advanced pancreatic cancer and that long lasting stable disease is considered beneficial to patients, clinical benefit rate (confirmed objective response or SD&gt;4 months) was used as the primary endpoint for antitumor activity in this study changed from objective response to for this patient population.</population>
          <units>Percentage of participants</units>
          <param>Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Bayesian inference of Overall Response Rate was measured for this arm instead. See the Bayesian inference of Overall Response rate - per irRC - mean results</measurement>
                    <measurement group_id="O2" value="5.6" lower_limit="0.4" upper_limit="15.3"/>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">Bayesian inference of Overall Response Rate was measured for this arm instead. See the Bayesian inference of Overall Response rate - per irRC - mean results</measurement>
                    <measurement group_id="O4" value="NA" lower_limit="NA" upper_limit="NA">Bayesian inference of Overall Response Rate was measured for this arm instead. See the Bayesian inference of Overall Response rate - per irRC - mean results</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 1b and Phase II: Progression Free Survival Based on Investigator Assessment as Per RECIST v1.1 and Per Immune Related Response Criteria (irRC) - Using Kaplan-Meier Method - Median</title>
        <description>Phase 1b and Phase II: Progression Free Survival. Progression is defined as a 20% increase in the sum of diameter of measurable lesions taking as reference the smallest sum of diameter recorded at or after baseline, or worsening of non-measurable lesions or the appearance of new lesions, using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) or Per Immune Related Response Criteria (irRC). Unlike RECIST 1.1, PD per irRC requires confirmation at a new assessment after at least 4 weeks - using Kaplan-Meier method - Median.</description>
        <time_frame>Up to year 4</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Ph Ib: MCS110 1 mg/kg Q3W + PDR001 100 mg Q3W</title>
            <description>Phase Ib: MCS110 1 mg/kg every 3 weeks (Q3W) + PDR001 100 mg Q3W</description>
          </group>
          <group group_id="O2">
            <title>Ph Ib: MCS110 3 mg/kg Q3W + PDR001 100 mg Q3W</title>
            <description>Phase Ib: MCS110 3 mg/kg Q3W + PDR001 100 mg Q3W</description>
          </group>
          <group group_id="O3">
            <title>Ph Ib: MCS110 3 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 3 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O4">
            <title>Ph Ib: MCS110 5 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 5 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O5">
            <title>Ph Ib: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O6">
            <title>Ph Ib: MCS110 10 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 10 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O7">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - TNBC</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Triple negative breast cancer (TNBC)</description>
          </group>
          <group group_id="O8">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - PC</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Pancreatic cancer (PC)</description>
          </group>
          <group group_id="O9">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - EC</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Endometrial cancer (EC)</description>
          </group>
          <group group_id="O10">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - ME</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Melanoma (ME)</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 1b and Phase II: Progression Free Survival Based on Investigator Assessment as Per RECIST v1.1 and Per Immune Related Response Criteria (irRC) - Using Kaplan-Meier Method - Median</title>
          <description>Phase 1b and Phase II: Progression Free Survival. Progression is defined as a 20% increase in the sum of diameter of measurable lesions taking as reference the smallest sum of diameter recorded at or after baseline, or worsening of non-measurable lesions or the appearance of new lesions, using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) or Per Immune Related Response Criteria (irRC). Unlike RECIST 1.1, PD per irRC requires confirmation at a new assessment after at least 4 weeks - using Kaplan-Meier method - Median.</description>
          <population>Full Analysis Set</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="11"/>
                <count group_id="O7" value="20"/>
                <count group_id="O8" value="20"/>
                <count group_id="O9" value="21"/>
                <count group_id="O10" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Median PFS - per RECIST v1.1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" lower_limit="1.1" upper_limit="14.8"/>
                    <measurement group_id="O2" value="1.3" lower_limit="1.3" upper_limit="2.7"/>
                    <measurement group_id="O3" value="1.3" lower_limit="0.8" upper_limit="1.3"/>
                    <measurement group_id="O4" value="1.1" lower_limit="0.6" upper_limit="1.3"/>
                    <measurement group_id="O5" value="1.3" lower_limit="0.5" upper_limit="4.0"/>
                    <measurement group_id="O6" value="1.2" lower_limit="0.6" upper_limit="2.4"/>
                    <measurement group_id="O7" value="1.6" lower_limit="1.4" upper_limit="2.8"/>
                    <measurement group_id="O8" value="1.3" lower_limit="1.2" upper_limit="1.4"/>
                    <measurement group_id="O9" value="1.3" lower_limit="1.2" upper_limit="1.4"/>
                    <measurement group_id="O10" value="2.4" lower_limit="1.4" upper_limit="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Median PFS - per iiRC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2" lower_limit="1.2" upper_limit="25.8"/>
                    <measurement group_id="O2" value="2.2" lower_limit="1.3" upper_limit="2.7"/>
                    <measurement group_id="O3" value="1.3" lower_limit="0.9" upper_limit="1.3"/>
                    <measurement group_id="O4" value="1.0" lower_limit="0.5" upper_limit="1.3"/>
                    <measurement group_id="O5" value="1.3" lower_limit="0.5" upper_limit="16.8"/>
                    <measurement group_id="O6" value="1.2" lower_limit="0.7" upper_limit="2.4"/>
                    <measurement group_id="O7" value="1.6" lower_limit="1.4" upper_limit="2.8"/>
                    <measurement group_id="O8" value="1.3" lower_limit="1.2" upper_limit="1.5"/>
                    <measurement group_id="O9" value="1.3" lower_limit="1.2" upper_limit="1.4"/>
                    <measurement group_id="O10" value="3.7" lower_limit="1.4" upper_limit="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 1b and Phase II: Overall Survival - Using Kaplan-Meier Method - Median</title>
        <description>Phase 1b and Phase II: Overall Survival - using Kaplan-Meier method - Median</description>
        <time_frame>Up to year 4</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Ph Ib: MCS110 1 mg/kg Q3W + PDR001 100 mg Q3W</title>
            <description>Phase Ib: MCS110 1 mg/kg every 3 weeks (Q3W) + PDR001 100 mg Q3W</description>
          </group>
          <group group_id="O2">
            <title>Ph Ib: MCS110 3 mg/kg Q3W + PDR001 100 mg Q3W</title>
            <description>Phase Ib: MCS110 3 mg/kg Q3W + PDR001 100 mg Q3W</description>
          </group>
          <group group_id="O3">
            <title>Ph Ib: MCS110 3 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 3 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O4">
            <title>Ph Ib: MCS110 5 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 5 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O5">
            <title>Ph Ib: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O6">
            <title>Ph Ib: MCS110 10 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 10 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O7">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - TNBC</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Triple negative breast cancer (TNBC)</description>
          </group>
          <group group_id="O8">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - PC</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Pancreatic cancer (PC)</description>
          </group>
          <group group_id="O9">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - EC</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Endometrial cancer (EC)</description>
          </group>
          <group group_id="O10">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - ME</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Melanoma (ME)</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 1b and Phase II: Overall Survival - Using Kaplan-Meier Method - Median</title>
          <description>Phase 1b and Phase II: Overall Survival - using Kaplan-Meier method - Median</description>
          <population>Full Analysis Set</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="11"/>
                <count group_id="O7" value="20"/>
                <count group_id="O8" value="20"/>
                <count group_id="O9" value="21"/>
                <count group_id="O10" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.3" lower_limit="3.1" upper_limit="26.6"/>
                    <measurement group_id="O2" value="9.6" lower_limit="3.8" upper_limit="12.2"/>
                    <measurement group_id="O3" value="4.2" lower_limit="1.5" upper_limit="7.9"/>
                    <measurement group_id="O4" value="2.8" lower_limit="1.2" upper_limit="3.8"/>
                    <measurement group_id="O5" value="22.8" lower_limit="1.1" upper_limit="26.8"/>
                    <measurement group_id="O6" value="5.7" lower_limit="1.2" upper_limit="8.2"/>
                    <measurement group_id="O7" value="8.9" lower_limit="5.6" upper_limit="16.6"/>
                    <measurement group_id="O8" value="2.6" lower_limit="1.8" upper_limit="5.0"/>
                    <measurement group_id="O9" value="11.7" lower_limit="9.2" upper_limit="14.6"/>
                    <measurement group_id="O10" value="19.7" lower_limit="9.2" upper_limit="20.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 1b and Phase II: Duration of Response (DOR)</title>
        <description>Phase 1b and Phase II: Duration of Response (DOR) per RECIST v1.1 and per immune related Response criteria (irRC)</description>
        <time_frame>4 years</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Ph Ib: MCS110 1 mg/kg Q3W + PDR001 100 mg Q3W</title>
            <description>Phase Ib: MCS110 1 mg/kg every 3 weeks (Q3W) + PDR001 100 mg Q3W</description>
          </group>
          <group group_id="O2">
            <title>Ph Ib: MCS110 3 mg/kg Q3W + PDR001 100 mg Q3W</title>
            <description>Phase Ib: MCS110 3 mg/kg Q3W + PDR001 100 mg Q3W</description>
          </group>
          <group group_id="O3">
            <title>Ph Ib: MCS110 3 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 3 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O4">
            <title>Ph Ib: MCS110 5 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 5 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O5">
            <title>Ph Ib: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O6">
            <title>Ph Ib: MCS110 10 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 10 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O7">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - TNBC</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Triple negative breast cancer (TNBC)</description>
          </group>
          <group group_id="O8">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - PC</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Pancreatic cancer (PC)</description>
          </group>
          <group group_id="O9">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - EC</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Endometrial cancer (EC)</description>
          </group>
          <group group_id="O10">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - ME</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Melanoma (ME)</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 1b and Phase II: Duration of Response (DOR)</title>
          <description>Phase 1b and Phase II: Duration of Response (DOR) per RECIST v1.1 and per immune related Response criteria (irRC)</description>
          <population>Full Analysis Set</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="11"/>
                <count group_id="O7" value="20"/>
                <count group_id="O8" value="20"/>
                <count group_id="O9" value="21"/>
                <count group_id="O10" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Duration of response(days) - based on RECIST v1.1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="372.0" lower_limit="372" upper_limit="372"/>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">The median is not available because there was an insufficient number of participants with events. The lower and upper limits are not applicable since there is no value for median.</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">The median is not available because there was an insufficient number of participants with events. The lower and upper limits are not applicable since there is no value for median.</measurement>
                    <measurement group_id="O4" value="NA" lower_limit="NA" upper_limit="NA">The median is not available because there was an insufficient number of participants with events. The lower and upper limits are not applicable since there is no value for median.</measurement>
                    <measurement group_id="O5" value="NA" lower_limit="NA" upper_limit="NA">The median is not available because there was an insufficient number of participants with events. The lower and upper limits are not applicable since there is no value for median.</measurement>
                    <measurement group_id="O6" value="155.0" lower_limit="155.0" upper_limit="155.0"/>
                    <measurement group_id="O7" value="169" lower_limit="169" upper_limit="169"/>
                    <measurement group_id="O8" value="NA" lower_limit="NA" upper_limit="NA">The median is not available because there was an insufficient number of participants with events. The lower and upper limits are not applicable since there is no value for median.</measurement>
                    <measurement group_id="O9" value="328.5" lower_limit="194" upper_limit="463"/>
                    <measurement group_id="O10" value="NA" lower_limit="NA" upper_limit="NA">The median is not available because there was an insufficient number of participants with events. The lower and upper limits are not applicable since there is no value for median.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration of response(days) - based on irRC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="372.0" lower_limit="372.0" upper_limit="372.0"/>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">The median is not available because there was an insufficient number of participants with events. The lower and upper limits are not applicable since there is no value for median.</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">The median is not available because there was an insufficient number of participants with events. The lower and upper limits are not applicable since there is no value for median.</measurement>
                    <measurement group_id="O4" value="NA" lower_limit="NA" upper_limit="NA">The median is not available because there was an insufficient number of participants with events. The lower and upper limits are not applicable since there is no value for median.</measurement>
                    <measurement group_id="O5" value="NA" lower_limit="NA" upper_limit="NA">The median is not available because there was an insufficient number of participants with events. The lower and upper limits are not applicable since there is no value for median.</measurement>
                    <measurement group_id="O6" value="155.0" lower_limit="155.0" upper_limit="155.0"/>
                    <measurement group_id="O7" value="169" lower_limit="169" upper_limit="169"/>
                    <measurement group_id="O8" value="NA" lower_limit="NA" upper_limit="NA">The median is not available because there was an insufficient number of participants with events. The lower and upper limits are not applicable since there is no value for median.</measurement>
                    <measurement group_id="O9" value="328.5" lower_limit="194" upper_limit="463"/>
                    <measurement group_id="O10" value="NA" lower_limit="NA" upper_limit="NA">The median is not available because there was an insufficient number of participants with events. The lower and upper limits are not applicable since there is no value for median.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 1b and Phase II: Disease Control Rate (DCR)</title>
        <description>Phase 1b and Phase II: Disease Control Rate (Complete response (CR) or Partial response (PR) or Stable disease (SD) &gt; 4 month)) per RECIST v1.1 and per immune related Response criteria (irRC)</description>
        <time_frame>4 years</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Ph Ib: MCS110 1 mg/kg Q3W + PDR001 100 mg Q3W</title>
            <description>Phase Ib: MCS110 1 mg/kg every 3 weeks (Q3W) + PDR001 100 mg Q3W</description>
          </group>
          <group group_id="O2">
            <title>Ph Ib: MCS110 3 mg/kg Q3W + PDR001 100 mg Q3W</title>
            <description>Phase Ib: MCS110 3 mg/kg Q3W + PDR001 100 mg Q3W</description>
          </group>
          <group group_id="O3">
            <title>Ph Ib: MCS110 3 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 3 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O4">
            <title>Ph Ib: MCS110 5 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 5 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O5">
            <title>Ph Ib: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O6">
            <title>Ph Ib: MCS110 10 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 10 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O7">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - TNBC</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Triple negative breast cancer (TNBC)</description>
          </group>
          <group group_id="O8">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - PC</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Pancreatic cancer (PC)</description>
          </group>
          <group group_id="O9">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - EC</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Endometrial cancer (EC)</description>
          </group>
          <group group_id="O10">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - ME</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Melanoma (ME)</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 1b and Phase II: Disease Control Rate (DCR)</title>
          <description>Phase 1b and Phase II: Disease Control Rate (Complete response (CR) or Partial response (PR) or Stable disease (SD) &gt; 4 month)) per RECIST v1.1 and per immune related Response criteria (irRC)</description>
          <population>Full Analysis Set</population>
          <units>Percentage</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="11"/>
                <count group_id="O7" value="20"/>
                <count group_id="O8" value="20"/>
                <count group_id="O9" value="21"/>
                <count group_id="O10" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Disease Control Rate - as per investigator based on RECIST v1.1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3" lower_limit="6.3" upper_limit="72.9"/>
                    <measurement group_id="O2" value="8.3" lower_limit="0.4" upper_limit="33.9"/>
                    <measurement group_id="O3" value="0" lower_limit="0.0" upper_limit="22.1"/>
                    <measurement group_id="O4" value="15.4" lower_limit="2.8" upper_limit="41.0"/>
                    <measurement group_id="O5" value="16.7" lower_limit="0.9" upper_limit="58.2"/>
                    <measurement group_id="O6" value="18.2" lower_limit="3.3" upper_limit="47.0"/>
                    <measurement group_id="O7" value="20.0" lower_limit="7.1" upper_limit="40.1"/>
                    <measurement group_id="O8" value="0" lower_limit="0.0" upper_limit="13.9"/>
                    <measurement group_id="O9" value="19.0" lower_limit="6.8" upper_limit="38.4"/>
                    <measurement group_id="O10" value="35.0" lower_limit="17.7" upper_limit="55.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Control Rate as per investigator based on irRC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0" lower_limit="15.3" upper_limit="84.7"/>
                    <measurement group_id="O2" value="8.3" lower_limit="0.4" upper_limit="33.9"/>
                    <measurement group_id="O3" value="0" lower_limit="0.0" upper_limit="22.1"/>
                    <measurement group_id="O4" value="15.4" lower_limit="2.8" upper_limit="41.0"/>
                    <measurement group_id="O5" value="33.3" lower_limit="6.3" upper_limit="72.9"/>
                    <measurement group_id="O6" value="18.2" lower_limit="3.3" upper_limit="47.0"/>
                    <measurement group_id="O7" value="20.0" lower_limit="7.1" upper_limit="40.1"/>
                    <measurement group_id="O8" value="5.0" lower_limit="0.3" upper_limit="21.6"/>
                    <measurement group_id="O9" value="19.0" lower_limit="6.8" upper_limit="38.4"/>
                    <measurement group_id="O10" value="45.0" lower_limit="25.9" upper_limit="65.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase II: Percentage of Participants With Adverse Events, as a Measure of Safety</title>
        <description>Phase II: To further characterize the safety and tolerability of MCS110 given in combination with PDR001</description>
        <time_frame>From start of treatment to a maximum timeframe of 92.4 weeks for phase II.</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - TNBC</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Triple negative breast cancer (TNBC)</description>
          </group>
          <group group_id="O2">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - PC</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Pancreatic cancer (PC)</description>
          </group>
          <group group_id="O3">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - EC</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Endometrial cancer (EC)</description>
          </group>
          <group group_id="O4">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - ME</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Melanoma (ME)</description>
          </group>
        </group_list>
        <measure>
          <title>Phase II: Percentage of Participants With Adverse Events, as a Measure of Safety</title>
          <description>Phase II: To further characterize the safety and tolerability of MCS110 given in combination with PDR001</description>
          <population>Safety Analysis Set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Adverse events - all grades</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="21"/>
                    <measurement group_id="O4" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adverse events - Treatment-related - all grades</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs - all grades</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs - Treatment-related - all grades</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatal SAEs - all grades</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatal SAEs - Treatment-related - all grades</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs leading to discontinuation - all grades</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs leading to discontinuation - Treatment-related - all grades</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs leading to dose adjustment / interruption - all grades</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs requiring additional therapy - all grades</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase Ib and Phase II: Immunogenicity MCS110</title>
        <description>Phase Ib and Phase II: Presence of anti-MCS110 antibodies</description>
        <time_frame>4 years</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Ph Ib: MCS110 1 mg/kg Q3W + PDR001 100 mg Q3W</title>
            <description>Phase Ib: MCS110 1 mg/kg every 3 weeks (Q3W) + PDR001 100 mg Q3W</description>
          </group>
          <group group_id="O2">
            <title>Ph Ib: MCS110 3 mg/kg Q3W + PDR001 100 mg Q3W</title>
            <description>Phase Ib: MCS110 3 mg/kg Q3W + PDR001 100 mg Q3W</description>
          </group>
          <group group_id="O3">
            <title>Ph Ib: MCS110 3 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 3 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O4">
            <title>Ph Ib: MCS110 5 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 5 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O5">
            <title>Ph Ib: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O6">
            <title>Ph Ib: MCS110 10 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 10 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O7">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - TNBC</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Triple negative breast cancer (TNBC)</description>
          </group>
          <group group_id="O8">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - PC</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Pancreatic cancer (PC)</description>
          </group>
          <group group_id="O9">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - EC</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Endometrial cancer (EC)</description>
          </group>
          <group group_id="O10">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - ME</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Melanoma (ME)</description>
          </group>
        </group_list>
        <measure>
          <title>Phase Ib and Phase II: Immunogenicity MCS110</title>
          <description>Phase Ib and Phase II: Presence of anti-MCS110 antibodies</description>
          <population>Full Analysis Set</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="11"/>
                <count group_id="O7" value="20"/>
                <count group_id="O8" value="20"/>
                <count group_id="O9" value="21"/>
                <count group_id="O10" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="11"/>
                    <measurement group_id="O7" value="19"/>
                    <measurement group_id="O8" value="19"/>
                    <measurement group_id="O9" value="17"/>
                    <measurement group_id="O10" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="4"/>
                    <measurement group_id="O10" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline positive, on treatment persistent positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline positive, on treatment only last positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline positive, on treatment any positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline positive, on treatment all negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline negative, on treatment persistent positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline negative, on treatment only last positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline negative, on treatment any positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline negative, on treatment all negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="12"/>
                    <measurement group_id="O8" value="16"/>
                    <measurement group_id="O9" value="14"/>
                    <measurement group_id="O10" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline missing, on treatment persistent positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline missing, on treatment only last positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline missing, on treatment any positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline missing, on treatment all negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase Ib and Phase II: Immunogenicity PDR001</title>
        <description>Phase Ib and Phase II: Presence of anti-PDR001 antibodies</description>
        <time_frame>4 years</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Ph Ib: MCS110 1 mg/kg Q3W + PDR001 100 mg Q3W</title>
            <description>Phase Ib: MCS110 1 mg/kg every 3 weeks (Q3W) + PDR001 100 mg Q3W</description>
          </group>
          <group group_id="O2">
            <title>Ph Ib: MCS110 3 mg/kg Q3W + PDR001 100 mg Q3W</title>
            <description>Phase Ib: MCS110 3 mg/kg Q3W + PDR001 100 mg Q3W</description>
          </group>
          <group group_id="O3">
            <title>Ph Ib: MCS110 3 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 3 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O4">
            <title>Ph Ib: MCS110 5 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 5 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O5">
            <title>Ph Ib: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O6">
            <title>Ph Ib: MCS110 10 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 10 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O7">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - TNBC</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Triple negative breast cancer (TNBC)</description>
          </group>
          <group group_id="O8">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - PC</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Pancreatic cancer (PC)</description>
          </group>
          <group group_id="O9">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - EC</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Endometrial cancer (EC)</description>
          </group>
          <group group_id="O10">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - ME</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Melanoma (ME)</description>
          </group>
        </group_list>
        <measure>
          <title>Phase Ib and Phase II: Immunogenicity PDR001</title>
          <description>Phase Ib and Phase II: Presence of anti-PDR001 antibodies</description>
          <population>Full Analysis Set</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="11"/>
                <count group_id="O7" value="20"/>
                <count group_id="O8" value="20"/>
                <count group_id="O9" value="21"/>
                <count group_id="O10" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="8"/>
                    <measurement group_id="O7" value="18"/>
                    <measurement group_id="O8" value="17"/>
                    <measurement group_id="O9" value="19"/>
                    <measurement group_id="O10" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="2"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline positive, on treatment persistent positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline positive, on treatment only last positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline positive, on treatment any positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline positive, on treatment all negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline negative, on treatment persistent positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline negative, on treatment only last positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="4"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline negative, on treatment any positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline negative, on treatment all negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="11"/>
                    <measurement group_id="O8" value="10"/>
                    <measurement group_id="O9" value="16"/>
                    <measurement group_id="O10" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline missing, on treatment persistent positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline missing, on treatment only last positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline missing, on treatment any positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline missing, on treatment all negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase Ib and Phase II: Pharmacokinetics of MCS110 - AUClast and AUCinf</title>
        <description>Phase Ib and Phase II: PK Parameters - AUClast, which is the AUC from time zero to the last measurable concentration sampling time (tlast) (mass × time&#xD;
× volume-1); and AUCinf, which is the AUC from time zero to infinity (mass × time × volume-1) - MCS110</description>
        <time_frame>cycle 1 (day 21) and cycle 4 (day 84)</time_frame>
        <population>Pharmacokinetic analysis set. Some patients were excluded because of missed visits, missed sampling, early termination, dosing outside the planned dose, or lost samples. There were some patients with AUClast but no AUCinf parameters because AUCinf could not be extrapolated from the data (i.e. the % of AUC extrapolated past the last time point is greater than 20% or the adjusted R squared parameter for the regression fit of the terminal phase of the PK profile is &lt; 0.75).</population>
        <group_list>
          <group group_id="O1">
            <title>Ph Ib: MCS110 1 mg/kg Q3W + PDR001 100 mg Q3W</title>
            <description>Phase Ib: MCS110 1 mg/kg every 3 weeks (Q3W) + PDR001 100 mg Q3W</description>
          </group>
          <group group_id="O2">
            <title>Ph Ib: MCS110 3 mg/kg Q3W + PDR001 100 mg Q3W</title>
            <description>Phase Ib: MCS110 3 mg/kg Q3W + PDR001 100 mg Q3W</description>
          </group>
          <group group_id="O3">
            <title>Ph Ib: MCS110 3 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 3 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O4">
            <title>Ph Ib: MCS110 5 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 5 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O5">
            <title>Ph Ib: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O6">
            <title>Ph Ib: MCS110 10 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 10 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O7">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - TNBC</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Triple negative breast cancer (TNBC)</description>
          </group>
          <group group_id="O8">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - PC</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Pancreatic cancer (PC)</description>
          </group>
          <group group_id="O9">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - EC</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Endometrial cancer (EC)</description>
          </group>
          <group group_id="O10">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - ME</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Melanoma (ME)</description>
          </group>
        </group_list>
        <measure>
          <title>Phase Ib and Phase II: Pharmacokinetics of MCS110 - AUClast and AUCinf</title>
          <description>Phase Ib and Phase II: PK Parameters - AUClast, which is the AUC from time zero to the last measurable concentration sampling time (tlast) (mass × time&#xD;
× volume-1); and AUCinf, which is the AUC from time zero to infinity (mass × time × volume-1) - MCS110</description>
          <population>Pharmacokinetic analysis set. Some patients were excluded because of missed visits, missed sampling, early termination, dosing outside the planned dose, or lost samples. There were some patients with AUClast but no AUCinf parameters because AUCinf could not be extrapolated from the data (i.e. the % of AUC extrapolated past the last time point is greater than 20% or the adjusted R squared parameter for the regression fit of the terminal phase of the PK profile is &lt; 0.75).</population>
          <units>day*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="11"/>
                <count group_id="O7" value="20"/>
                <count group_id="O8" value="19"/>
                <count group_id="O9" value="20"/>
                <count group_id="O10" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUClast (day*ng/mL) - cycle 1 - day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="10"/>
                    <count group_id="O7" value="16"/>
                    <count group_id="O8" value="16"/>
                    <count group_id="O9" value="16"/>
                    <count group_id="O10" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46900" spread="9080"/>
                    <measurement group_id="O2" value="343000" spread="142000"/>
                    <measurement group_id="O3" value="249000" spread="93400"/>
                    <measurement group_id="O4" value="490000" spread="149000"/>
                    <measurement group_id="O5" value="909000" spread="233000"/>
                    <measurement group_id="O6" value="1090000" spread="231000"/>
                    <measurement group_id="O7" value="1200000" spread="507000"/>
                    <measurement group_id="O8" value="1090000" spread="352000"/>
                    <measurement group_id="O9" value="1120000" spread="440000"/>
                    <measurement group_id="O10" value="1270000" spread="335000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUCinf (day*ng/mL) - cycle 1 - day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="5"/>
                    <count group_id="O6" value="5"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                    <count group_id="O9" value="0"/>
                    <count group_id="O10" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50100" spread="11600"/>
                    <measurement group_id="O2" value="383000" spread="178000"/>
                    <measurement group_id="O3" value="330000" spread="73400"/>
                    <measurement group_id="O4" value="560000" spread="177000"/>
                    <measurement group_id="O5" value="1020000" spread="336000"/>
                    <measurement group_id="O6" value="988000" spread="116000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUClast (day*ng/mL) - cycle 4 - day 84</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="3"/>
                    <count group_id="O7" value="4"/>
                    <count group_id="O8" value="3"/>
                    <count group_id="O9" value="4"/>
                    <count group_id="O10" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41000" spread="22800"/>
                    <measurement group_id="O2" value="213000" spread="92200"/>
                    <measurement group_id="O3" value="232000" spread="99300"/>
                    <measurement group_id="O4" value="710000" spread="171000"/>
                    <measurement group_id="O5" value="1520000" spread="353000"/>
                    <measurement group_id="O6" value="1200000" spread="1030000"/>
                    <measurement group_id="O7" value="1200000" spread="389000"/>
                    <measurement group_id="O8" value="918000" spread="102000"/>
                    <measurement group_id="O9" value="1010000" spread="337000"/>
                    <measurement group_id="O10" value="1240000" spread="499000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUCinf (day*ng/mL) - cycle 4 - day 84</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="1"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="1"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                    <count group_id="O9" value="0"/>
                    <count group_id="O10" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42300" spread="21900"/>
                    <measurement group_id="O2" value="260000" spread="73500"/>
                    <measurement group_id="O3" value="253000" spread="114000"/>
                    <measurement group_id="O4" value="619000" spread="NA">SD is not applicable for an analysis with 1 participant</measurement>
                    <measurement group_id="O6" value="769000" spread="NA">SD is not applicable for an analysis with 1 participant</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase Ib and Phase II: Pharmacokinetics of PDR001 - AUClast and AUCinf</title>
        <description>Phase Ib and Phase II: Pharmacokinetics (PK) Parameters - AUClast, which is the AUC from time zero to the last measurable concentration sampling time (tlast) (mass × time&#xD;
× volume-1); and AUCinf, which is the AUC from time zero to infinity (mass × time × volume-1) and AUCinf - PDR001</description>
        <time_frame>cycle 1 (day 21) and cycle 4 (day 84)</time_frame>
        <population>Pharmacokinetic analysis set. Some patients were excluded because of missed visits, missed sampling, early termination, dosing outside the planned dose, or lost samples. There were some patients with AUClast but no AUCinf parameters because AUCinf could not be extrapolated from the data (i.e. the % of AUC extrapolated past the last time point is greater than 20% or the adjusted R squared parameter for the regression fit of the terminal phase of the PK profile is &lt; 0.75).</population>
        <group_list>
          <group group_id="O1">
            <title>Ph Ib: MCS110 1 mg/kg Q3W + PDR001 100 mg Q3W</title>
            <description>Phase Ib: MCS110 1 mg/kg every 3 weeks (Q3W) + PDR001 100 mg Q3W</description>
          </group>
          <group group_id="O2">
            <title>Ph Ib: MCS110 3 mg/kg Q3W + PDR001 100 mg Q3W</title>
            <description>Phase Ib: MCS110 3 mg/kg Q3W + PDR001 100 mg Q3W</description>
          </group>
          <group group_id="O3">
            <title>Ph Ib: MCS110 3 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 3 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O4">
            <title>Ph Ib: MCS110 5 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 5 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O5">
            <title>Ph Ib: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O6">
            <title>Ph Ib: MCS110 10 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 10 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O7">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - TNBC</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Triple negative breast cancer (TNBC)</description>
          </group>
          <group group_id="O8">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - PC</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Pancreatic cancer (PC)</description>
          </group>
          <group group_id="O9">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - EC</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Endometrial cancer (EC)</description>
          </group>
          <group group_id="O10">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - ME</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Melanoma (ME)</description>
          </group>
        </group_list>
        <measure>
          <title>Phase Ib and Phase II: Pharmacokinetics of PDR001 - AUClast and AUCinf</title>
          <description>Phase Ib and Phase II: Pharmacokinetics (PK) Parameters - AUClast, which is the AUC from time zero to the last measurable concentration sampling time (tlast) (mass × time&#xD;
× volume-1); and AUCinf, which is the AUC from time zero to infinity (mass × time × volume-1) and AUCinf - PDR001</description>
          <population>Pharmacokinetic analysis set. Some patients were excluded because of missed visits, missed sampling, early termination, dosing outside the planned dose, or lost samples. There were some patients with AUClast but no AUCinf parameters because AUCinf could not be extrapolated from the data (i.e. the % of AUC extrapolated past the last time point is greater than 20% or the adjusted R squared parameter for the regression fit of the terminal phase of the PK profile is &lt; 0.75).</population>
          <units>day*ug/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="11"/>
                <count group_id="O7" value="20"/>
                <count group_id="O8" value="19"/>
                <count group_id="O9" value="20"/>
                <count group_id="O10" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUClast (day*ug/mL) - cycle 1 - day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="13"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="20"/>
                    <count group_id="O8" value="18"/>
                    <count group_id="O9" value="19"/>
                    <count group_id="O10" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="229" spread="68.3"/>
                    <measurement group_id="O2" value="271" spread="53.8"/>
                    <measurement group_id="O3" value="651" spread="322"/>
                    <measurement group_id="O4" value="604" spread="309"/>
                    <measurement group_id="O5" value="581" spread="147"/>
                    <measurement group_id="O6" value="450" spread="135"/>
                    <measurement group_id="O7" value="825" spread="402"/>
                    <measurement group_id="O8" value="782" spread="264"/>
                    <measurement group_id="O9" value="764" spread="311"/>
                    <measurement group_id="O10" value="782" spread="307"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUCinf (day*ug/mL) - cycle 1 - day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="1"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                    <count group_id="O9" value="0"/>
                    <count group_id="O10" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="274" spread="NA">SD is not applicable for an analysis with 1 participant</measurement>
                    <measurement group_id="O3" value="610" spread="NA">SD is not applicable for an analysis with 1 participant</measurement>
                    <measurement group_id="O5" value="747" spread="NA">SD is not applicable for an analysis with 1 participant</measurement>
                    <measurement group_id="O6" value="710" spread="NA">SD is not applicable for an analysis with 1 participant</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUClast (day*ug/mL) - cycle 4 - day 84</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="3"/>
                    <count group_id="O7" value="5"/>
                    <count group_id="O8" value="3"/>
                    <count group_id="O9" value="4"/>
                    <count group_id="O10" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="369" spread="26.4"/>
                    <measurement group_id="O2" value="330" spread="182"/>
                    <measurement group_id="O3" value="1020" spread="526"/>
                    <measurement group_id="O4" value="2020" spread="1170"/>
                    <measurement group_id="O5" value="954" spread="179"/>
                    <measurement group_id="O6" value="718" spread="288"/>
                    <measurement group_id="O7" value="1170" spread="388"/>
                    <measurement group_id="O8" value="1330" spread="555"/>
                    <measurement group_id="O9" value="1660" spread="283"/>
                    <measurement group_id="O10" value="1260" spread="533"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUCinf (day*ug/mL) - cycle 4 - day 84</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                    <count group_id="O9" value="0"/>
                    <count group_id="O10" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="196" spread="NA">SD is not applicable for an analysis with 1 participant</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase Ib and Phase II: Pharmacokinetics of MCS110 - Cmax and Clast</title>
        <description>Phase Ib and Phase II: PK Parameters - Cmax, which is the maximum (peak) observed plasma, blood, serum, or other body fluid drug concentration after single dose administration (mass × volume-1); and Clast - MCS110</description>
        <time_frame>cycle 1 (day 21) and cycle 4 (day 84)</time_frame>
        <population>Pharmacokinetic analysis set. Some patients were excluded from the PK parameter analysis because of missed visits, missed sampling, early termination, dosing outside the planned dose, or lost samples.</population>
        <group_list>
          <group group_id="O1">
            <title>Ph Ib: MCS110 1 mg/kg Q3W + PDR001 100 mg Q3W</title>
            <description>Phase Ib: MCS110 1 mg/kg every 3 weeks (Q3W) + PDR001 100 mg Q3W</description>
          </group>
          <group group_id="O2">
            <title>Ph Ib: MCS110 3 mg/kg Q3W + PDR001 100 mg Q3W</title>
            <description>Phase Ib: MCS110 3 mg/kg Q3W + PDR001 100 mg Q3W</description>
          </group>
          <group group_id="O3">
            <title>Ph Ib: MCS110 3 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 3 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O4">
            <title>Ph Ib: MCS110 5 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 5 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O5">
            <title>Ph Ib: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O6">
            <title>Ph Ib: MCS110 10 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 10 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O7">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - TNBC</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Triple negative breast cancer (TNBC)</description>
          </group>
          <group group_id="O8">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - PC</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Pancreatic cancer (PC)</description>
          </group>
          <group group_id="O9">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - EC</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Endometrial cancer (EC)</description>
          </group>
          <group group_id="O10">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - ME</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Melanoma (ME)</description>
          </group>
        </group_list>
        <measure>
          <title>Phase Ib and Phase II: Pharmacokinetics of MCS110 - Cmax and Clast</title>
          <description>Phase Ib and Phase II: PK Parameters - Cmax, which is the maximum (peak) observed plasma, blood, serum, or other body fluid drug concentration after single dose administration (mass × volume-1); and Clast - MCS110</description>
          <population>Pharmacokinetic analysis set. Some patients were excluded from the PK parameter analysis because of missed visits, missed sampling, early termination, dosing outside the planned dose, or lost samples.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="11"/>
                <count group_id="O7" value="20"/>
                <count group_id="O8" value="19"/>
                <count group_id="O9" value="20"/>
                <count group_id="O10" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cmax (ng/mL) - cycle 1 - day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="10"/>
                    <count group_id="O7" value="16"/>
                    <count group_id="O8" value="16"/>
                    <count group_id="O9" value="16"/>
                    <count group_id="O10" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17400" spread="1870"/>
                    <measurement group_id="O2" value="58800" spread="16900"/>
                    <measurement group_id="O3" value="56700" spread="17800"/>
                    <measurement group_id="O4" value="96900" spread="28600"/>
                    <measurement group_id="O5" value="122000" spread="17100"/>
                    <measurement group_id="O6" value="186000" spread="54000"/>
                    <measurement group_id="O7" value="158000" spread="44800"/>
                    <measurement group_id="O8" value="130000" spread="38400"/>
                    <measurement group_id="O9" value="134000" spread="64900"/>
                    <measurement group_id="O10" value="151000" spread="42500"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clast (ng/mL) - cycle 1 - day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="10"/>
                    <count group_id="O7" value="16"/>
                    <count group_id="O8" value="16"/>
                    <count group_id="O9" value="16"/>
                    <count group_id="O10" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1120" spread="795"/>
                    <measurement group_id="O2" value="1290" spread="2760"/>
                    <measurement group_id="O3" value="6600" spread="6370"/>
                    <measurement group_id="O4" value="9130" spread="11500"/>
                    <measurement group_id="O5" value="15100" spread="9070"/>
                    <measurement group_id="O6" value="28700" spread="27800"/>
                    <measurement group_id="O7" value="33000" spread="21300"/>
                    <measurement group_id="O8" value="12900" spread="10700"/>
                    <measurement group_id="O9" value="24500" spread="20100"/>
                    <measurement group_id="O10" value="17500" spread="11400"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax (ng/mL) -- cycle 4 - day 84</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="3"/>
                    <count group_id="O7" value="4"/>
                    <count group_id="O8" value="3"/>
                    <count group_id="O9" value="4"/>
                    <count group_id="O10" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13500" spread="5580"/>
                    <measurement group_id="O2" value="53000" spread="9790"/>
                    <measurement group_id="O3" value="48900" spread="14100"/>
                    <measurement group_id="O4" value="76400" spread="24000"/>
                    <measurement group_id="O5" value="176000" spread="19800"/>
                    <measurement group_id="O6" value="189000" spread="29400"/>
                    <measurement group_id="O7" value="159000" spread="39800"/>
                    <measurement group_id="O8" value="152000" spread="58000"/>
                    <measurement group_id="O9" value="128000" spread="42600"/>
                    <measurement group_id="O10" value="147000" spread="38300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clast (ng/mL) - cycle 4 - day 84</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="3"/>
                    <count group_id="O7" value="4"/>
                    <count group_id="O8" value="3"/>
                    <count group_id="O9" value="4"/>
                    <count group_id="O10" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="510" spread="457"/>
                    <measurement group_id="O2" value="5700" spread="10300"/>
                    <measurement group_id="O3" value="3490" spread="2410"/>
                    <measurement group_id="O4" value="7350" spread="5870"/>
                    <measurement group_id="O5" value="45100" spread="12400"/>
                    <measurement group_id="O6" value="34100" spread="29800"/>
                    <measurement group_id="O7" value="57600" spread="45000"/>
                    <measurement group_id="O8" value="33300" spread="42600"/>
                    <measurement group_id="O9" value="18600" spread="21700"/>
                    <measurement group_id="O10" value="29400" spread="20700"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase Ib and Phase II: Pharmacokinetics of PDR001 - Cmax and Clast</title>
        <description>Phase Ib and Phase II: PK Parameters - Cmax, which is the maximum (peak) observed plasma, blood, serum, or other body fluid drug concentration after single dose administration (mass × volume-1); and Clast - PDR001</description>
        <time_frame>cycle 1 (day 21) and cycle 4 (day 84)</time_frame>
        <population>Pharmacokinetic analysis set. Some patients were excluded from the PK parameter analysis because of missed visits, missed sampling, early termination, dosing outside the planned dose, or lost samples.</population>
        <group_list>
          <group group_id="O1">
            <title>Ph Ib: MCS110 1 mg/kg Q3W + PDR001 100 mg Q3W</title>
            <description>Phase Ib: MCS110 1 mg/kg every 3 weeks (Q3W) + PDR001 100 mg Q3W</description>
          </group>
          <group group_id="O2">
            <title>Ph Ib: MCS110 3 mg/kg Q3W + PDR001 100 mg Q3W</title>
            <description>Phase Ib: MCS110 3 mg/kg Q3W + PDR001 100 mg Q3W</description>
          </group>
          <group group_id="O3">
            <title>Ph Ib: MCS110 3 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 3 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O4">
            <title>Ph Ib: MCS110 5 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 5 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O5">
            <title>Ph Ib: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O6">
            <title>Ph Ib: MCS110 10 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 10 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O7">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - TNBC</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Triple negative breast cancer (TNBC)</description>
          </group>
          <group group_id="O8">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - PC</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Pancreatic cancer (PC)</description>
          </group>
          <group group_id="O9">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - EC</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Endometrial cancer (EC)</description>
          </group>
          <group group_id="O10">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - ME</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Melanoma (ME)</description>
          </group>
        </group_list>
        <measure>
          <title>Phase Ib and Phase II: Pharmacokinetics of PDR001 - Cmax and Clast</title>
          <description>Phase Ib and Phase II: PK Parameters - Cmax, which is the maximum (peak) observed plasma, blood, serum, or other body fluid drug concentration after single dose administration (mass × volume-1); and Clast - PDR001</description>
          <population>Pharmacokinetic analysis set. Some patients were excluded from the PK parameter analysis because of missed visits, missed sampling, early termination, dosing outside the planned dose, or lost samples.</population>
          <units>ug/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="11"/>
                <count group_id="O7" value="20"/>
                <count group_id="O8" value="19"/>
                <count group_id="O9" value="20"/>
                <count group_id="O10" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cmax (ug/mL) - cycle 1 - day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="13"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="20"/>
                    <count group_id="O8" value="18"/>
                    <count group_id="O9" value="19"/>
                    <count group_id="O10" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24" spread="9.52"/>
                    <measurement group_id="O2" value="29.5" spread="6.56"/>
                    <measurement group_id="O3" value="73.4" spread="22.3"/>
                    <measurement group_id="O4" value="77" spread="24.3"/>
                    <measurement group_id="O5" value="76.6" spread="36.8"/>
                    <measurement group_id="O6" value="64.2" spread="20.4"/>
                    <measurement group_id="O7" value="94.5" spread="27.4"/>
                    <measurement group_id="O8" value="75.3" spread="23.9"/>
                    <measurement group_id="O9" value="80.2" spread="24"/>
                    <measurement group_id="O10" value="70.3" spread="21.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clast (ug/mL) - cycle 1 - day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="13"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="20"/>
                    <count group_id="O8" value="18"/>
                    <count group_id="O9" value="19"/>
                    <count group_id="O10" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.73" spread="2.97"/>
                    <measurement group_id="O2" value="7.24" spread="2.95"/>
                    <measurement group_id="O3" value="19.4" spread="11.7"/>
                    <measurement group_id="O4" value="26.4" spread="11.8"/>
                    <measurement group_id="O5" value="22.7" spread="12.8"/>
                    <measurement group_id="O6" value="17.2" spread="8.67"/>
                    <measurement group_id="O7" value="34.5" spread="13.3"/>
                    <measurement group_id="O8" value="24" spread="12"/>
                    <measurement group_id="O9" value="22.8" spread="9.44"/>
                    <measurement group_id="O10" value="24.4" spread="14.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax (ug/mL) -- cycle 4 - day 84</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="3"/>
                    <count group_id="O7" value="5"/>
                    <count group_id="O8" value="3"/>
                    <count group_id="O9" value="4"/>
                    <count group_id="O10" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.5" spread="9.3"/>
                    <measurement group_id="O2" value="36.8" spread="10.5"/>
                    <measurement group_id="O3" value="126" spread="54.6"/>
                    <measurement group_id="O4" value="153" spread="22.6"/>
                    <measurement group_id="O5" value="92" spread="22.1"/>
                    <measurement group_id="O6" value="85.9" spread="16.8"/>
                    <measurement group_id="O7" value="123" spread="56.8"/>
                    <measurement group_id="O8" value="127" spread="7"/>
                    <measurement group_id="O9" value="122" spread="23.6"/>
                    <measurement group_id="O10" value="108" spread="23.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clast (ug/mL) - cycle 4 - day 84</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="3"/>
                    <count group_id="O7" value="5"/>
                    <count group_id="O8" value="3"/>
                    <count group_id="O9" value="4"/>
                    <count group_id="O10" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.7" spread="2.25"/>
                    <measurement group_id="O2" value="14.5" spread="8.47"/>
                    <measurement group_id="O3" value="65.1" spread="37.6"/>
                    <measurement group_id="O4" value="71" spread="6.65"/>
                    <measurement group_id="O5" value="47.5" spread="25.7"/>
                    <measurement group_id="O6" value="35.6" spread="14.7"/>
                    <measurement group_id="O7" value="81.4" spread="43.6"/>
                    <measurement group_id="O8" value="62.1" spread="9.93"/>
                    <measurement group_id="O9" value="48.8" spread="20.6"/>
                    <measurement group_id="O10" value="51.3" spread="23.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase Ib and Phase II: Pharmacokinetics of MCS110 - Tmax</title>
        <description>Phase Ib and Phase II: PK Parameters - Tmax, which is the time to reach maximum (peak) plasma, blood, serum, or other body fluid drug concentration after single dose administration (time) - MCS110</description>
        <time_frame>cycle 1 (day 21) and cycle 4 (day 84)</time_frame>
        <population>Pharmacokinetic analysis set. Some patients were excluded from the PK parameter analysis because of missed visits, missed sampling, early termination, dosing outside the planned dose, or lost samples.</population>
        <group_list>
          <group group_id="O1">
            <title>Ph Ib: MCS110 1 mg/kg Q3W + PDR001 100 mg Q3W</title>
            <description>Phase Ib: MCS110 1 mg/kg every 3 weeks (Q3W) + PDR001 100 mg Q3W</description>
          </group>
          <group group_id="O2">
            <title>Ph Ib: MCS110 3 mg/kg Q3W + PDR001 100 mg Q3W</title>
            <description>Phase Ib: MCS110 3 mg/kg Q3W + PDR001 100 mg Q3W</description>
          </group>
          <group group_id="O3">
            <title>Ph Ib: MCS110 3 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 3 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O4">
            <title>Ph Ib: MCS110 5 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 5 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O5">
            <title>Ph Ib: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O6">
            <title>Ph Ib: MCS110 10 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 10 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O7">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - TNBC</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Triple negative breast cancer (TNBC)</description>
          </group>
          <group group_id="O8">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - PC</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Pancreatic cancer (PC)</description>
          </group>
          <group group_id="O9">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - EC</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Endometrial cancer (EC)</description>
          </group>
          <group group_id="O10">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - ME</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Melanoma (ME)</description>
          </group>
        </group_list>
        <measure>
          <title>Phase Ib and Phase II: Pharmacokinetics of MCS110 - Tmax</title>
          <description>Phase Ib and Phase II: PK Parameters - Tmax, which is the time to reach maximum (peak) plasma, blood, serum, or other body fluid drug concentration after single dose administration (time) - MCS110</description>
          <population>Pharmacokinetic analysis set. Some patients were excluded from the PK parameter analysis because of missed visits, missed sampling, early termination, dosing outside the planned dose, or lost samples.</population>
          <units>hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="11"/>
                <count group_id="O7" value="20"/>
                <count group_id="O8" value="19"/>
                <count group_id="O9" value="20"/>
                <count group_id="O10" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Tmax (h) - cycle 1 - day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="10"/>
                    <count group_id="O7" value="16"/>
                    <count group_id="O8" value="16"/>
                    <count group_id="O9" value="16"/>
                    <count group_id="O10" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.02" lower_limit="1.5" upper_limit="2.08"/>
                    <measurement group_id="O2" value="1.92" lower_limit="0.5" upper_limit="23.7"/>
                    <measurement group_id="O3" value="2.08" lower_limit="1.5" upper_limit="22.2"/>
                    <measurement group_id="O4" value="2.13" lower_limit="1.92" upper_limit="24"/>
                    <measurement group_id="O5" value="2.06" lower_limit="2" upper_limit="24.4"/>
                    <measurement group_id="O6" value="2.04" lower_limit="1.92" upper_limit="26.2"/>
                    <measurement group_id="O7" value="2.01" lower_limit="0.5" upper_limit="162"/>
                    <measurement group_id="O8" value="2.08" lower_limit="1.92" upper_limit="2.28"/>
                    <measurement group_id="O9" value="2.09" lower_limit="2" upper_limit="163"/>
                    <measurement group_id="O10" value="2.08" lower_limit="1.5" upper_limit="188"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tmax (h) - cycle 4 - day 84</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="3"/>
                    <count group_id="O7" value="4"/>
                    <count group_id="O8" value="3"/>
                    <count group_id="O9" value="4"/>
                    <count group_id="O10" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="2" upper_limit="2"/>
                    <measurement group_id="O2" value="2.05" lower_limit="0.5" upper_limit="2.08"/>
                    <measurement group_id="O3" value="2.03" lower_limit="2" upper_limit="23.7"/>
                    <measurement group_id="O4" value="13" lower_limit="2.02" upper_limit="24"/>
                    <measurement group_id="O5" value="2" lower_limit="2" upper_limit="20.8"/>
                    <measurement group_id="O6" value="2.03" lower_limit="1.98" upper_limit="21.3"/>
                    <measurement group_id="O7" value="2" lower_limit="1.92" upper_limit="2.12"/>
                    <measurement group_id="O8" value="2.02" lower_limit="1.98" upper_limit="2.08"/>
                    <measurement group_id="O9" value="2.04" lower_limit="2" upper_limit="2.12"/>
                    <measurement group_id="O10" value="2.05" lower_limit="2" upper_limit="2.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase Ib and Phase II: Pharmacokinetics of PDR001 - Tmax</title>
        <description>Phase Ib and Phase II: PK Parameters - Tmax, which is the time to reach maximum (peak) plasma, blood, serum, or other body fluid drug concentration after single dose administration (time) - PDR001</description>
        <time_frame>cycle 1 (day 21) and cycle 4 (day 84)</time_frame>
        <population>Pharmacokinetic analysis set. Some patients were excluded from the PK parameter analysis because of missed visits, missed sampling, early termination, dosing outside the planned dose, or lost samples.</population>
        <group_list>
          <group group_id="O1">
            <title>Ph Ib: MCS110 1 mg/kg Q3W + PDR001 100 mg Q3W</title>
            <description>Phase Ib: MCS110 1 mg/kg every 3 weeks (Q3W) + PDR001 100 mg Q3W</description>
          </group>
          <group group_id="O2">
            <title>Ph Ib: MCS110 3 mg/kg Q3W + PDR001 100 mg Q3W</title>
            <description>Phase Ib: MCS110 3 mg/kg Q3W + PDR001 100 mg Q3W</description>
          </group>
          <group group_id="O3">
            <title>Ph Ib: MCS110 3 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 3 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O4">
            <title>Ph Ib: MCS110 5 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 5 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O5">
            <title>Ph Ib: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O6">
            <title>Ph Ib: MCS110 10 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 10 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O7">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - TNBC</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Triple negative breast cancer (TNBC)</description>
          </group>
          <group group_id="O8">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - PC</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Pancreatic cancer (PC)</description>
          </group>
          <group group_id="O9">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - EC</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Endometrial cancer (EC)</description>
          </group>
          <group group_id="O10">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - ME</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Melanoma (ME)</description>
          </group>
        </group_list>
        <measure>
          <title>Phase Ib and Phase II: Pharmacokinetics of PDR001 - Tmax</title>
          <description>Phase Ib and Phase II: PK Parameters - Tmax, which is the time to reach maximum (peak) plasma, blood, serum, or other body fluid drug concentration after single dose administration (time) - PDR001</description>
          <population>Pharmacokinetic analysis set. Some patients were excluded from the PK parameter analysis because of missed visits, missed sampling, early termination, dosing outside the planned dose, or lost samples.</population>
          <units>hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="11"/>
                <count group_id="O7" value="20"/>
                <count group_id="O8" value="19"/>
                <count group_id="O9" value="20"/>
                <count group_id="O10" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Tmax (h) - cycle 1 - day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="13"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="20"/>
                    <count group_id="O8" value="18"/>
                    <count group_id="O9" value="19"/>
                    <count group_id="O10" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.5" lower_limit="1.48" upper_limit="26"/>
                    <measurement group_id="O2" value="2.08" lower_limit="1.5" upper_limit="25.5"/>
                    <measurement group_id="O3" value="1.53" lower_limit="1" upper_limit="26.5"/>
                    <measurement group_id="O4" value="1.57" lower_limit="1.5" upper_limit="22.3"/>
                    <measurement group_id="O5" value="1.53" lower_limit="0.983" upper_limit="25.8"/>
                    <measurement group_id="O6" value="1.52" lower_limit="1.5" upper_limit="22.8"/>
                    <measurement group_id="O7" value="1.5" lower_limit="1" upper_limit="168"/>
                    <measurement group_id="O8" value="1.5" lower_limit="0.5" upper_limit="3.22"/>
                    <measurement group_id="O9" value="1.5" lower_limit="1.42" upper_limit="166"/>
                    <measurement group_id="O10" value="1.5" lower_limit="1.45" upper_limit="624"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tmax (h) - cycle 4 - day 84</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="3"/>
                    <count group_id="O7" value="5"/>
                    <count group_id="O8" value="3"/>
                    <count group_id="O9" value="4"/>
                    <count group_id="O10" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.52" lower_limit="1.5" upper_limit="22.4"/>
                    <measurement group_id="O2" value="1.53" lower_limit="0" upper_limit="23.7"/>
                    <measurement group_id="O3" value="1.2" lower_limit="0" upper_limit="1.5"/>
                    <measurement group_id="O4" value="1.57" lower_limit="1.55" upper_limit="1.58"/>
                    <measurement group_id="O5" value="1.5" lower_limit="1.5" upper_limit="3.42"/>
                    <measurement group_id="O6" value="1.45" lower_limit="1.43" upper_limit="2.92"/>
                    <measurement group_id="O7" value="1.53" lower_limit="1.5" upper_limit="165"/>
                    <measurement group_id="O8" value="1.47" lower_limit="1.42" upper_limit="1.48"/>
                    <measurement group_id="O9" value="1.54" lower_limit="1.48" upper_limit="1.62"/>
                    <measurement group_id="O10" value="1.5" lower_limit="1.43" upper_limit="1.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase Ib and Phase II: Pharmacokinetics of MCS110 - T1/2</title>
        <description>Phase Ib and Phase II: PK Parameters - T1/2, which is the terminal half-life associated with the terminal slope of a semi logarithmic concentration time curve (time) - MCS110</description>
        <time_frame>cycle 1 (day 21) and cycle 4 (day 84)</time_frame>
        <population>Pharmacokinetic analysis set. Some patients were excluded from the PK parameter analysis because of missed visits, missed sampling, early termination, dosing outside the planned dose, or lost samples.</population>
        <group_list>
          <group group_id="O1">
            <title>Ph Ib: MCS110 1 mg/kg Q3W + PDR001 100 mg Q3W</title>
            <description>Phase Ib: MCS110 1 mg/kg every 3 weeks (Q3W) + PDR001 100 mg Q3W</description>
          </group>
          <group group_id="O2">
            <title>Ph Ib: MCS110 3 mg/kg Q3W + PDR001 100 mg Q3W</title>
            <description>Phase Ib: MCS110 3 mg/kg Q3W + PDR001 100 mg Q3W</description>
          </group>
          <group group_id="O3">
            <title>Ph Ib: MCS110 3 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 3 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O4">
            <title>Ph Ib: MCS110 5 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 5 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O5">
            <title>Ph Ib: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O6">
            <title>Ph Ib: MCS110 10 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 10 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O7">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - TNBC</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Triple negative breast cancer (TNBC)</description>
          </group>
          <group group_id="O8">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - PC</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Pancreatic cancer (PC)</description>
          </group>
          <group group_id="O9">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - EC</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Endometrial cancer (EC)</description>
          </group>
          <group group_id="O10">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - ME</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Melanoma (ME)</description>
          </group>
        </group_list>
        <measure>
          <title>Phase Ib and Phase II: Pharmacokinetics of MCS110 - T1/2</title>
          <description>Phase Ib and Phase II: PK Parameters - T1/2, which is the terminal half-life associated with the terminal slope of a semi logarithmic concentration time curve (time) - MCS110</description>
          <population>Pharmacokinetic analysis set. Some patients were excluded from the PK parameter analysis because of missed visits, missed sampling, early termination, dosing outside the planned dose, or lost samples.</population>
          <units>day</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="11"/>
                <count group_id="O7" value="20"/>
                <count group_id="O8" value="19"/>
                <count group_id="O9" value="20"/>
                <count group_id="O10" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>T1/2 (day) - cycle 1 - day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="5"/>
                    <count group_id="O6" value="5"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                    <count group_id="O9" value="0"/>
                    <count group_id="O10" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" lower_limit="1.25" upper_limit="2.38"/>
                    <measurement group_id="O2" value="2.16" lower_limit="1.68" upper_limit="6.71"/>
                    <measurement group_id="O3" value="3.3" lower_limit="1.85" upper_limit="5.32"/>
                    <measurement group_id="O4" value="3.48" lower_limit="1.73" upper_limit="7.82"/>
                    <measurement group_id="O5" value="6.35" lower_limit="2.17" upper_limit="8.05"/>
                    <measurement group_id="O6" value="4.36" lower_limit="2.25" upper_limit="6.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T1/2 (day) - cycle 4 - day 84</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="1"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="1"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                    <count group_id="O9" value="0"/>
                    <count group_id="O10" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.77" lower_limit="1.23" upper_limit="1.81"/>
                    <measurement group_id="O2" value="1.53" lower_limit="1.03" upper_limit="2.49"/>
                    <measurement group_id="O3" value="4.08" lower_limit="1.41" upper_limit="4.26"/>
                    <measurement group_id="O4" value="6.32" lower_limit="6.32" upper_limit="6.32"/>
                    <measurement group_id="O6" value="4.82" lower_limit="4.82" upper_limit="4.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase Ib and Phase II: Pharmacokinetics of PDR001 - T1/2</title>
        <description>Phase Ib and Phase II: PK Parameters - T1/2, which is the terminal half-life associated with the terminal slope of a semi logarithmic concentration time curve (time) - PDR001</description>
        <time_frame>cycle 1 (day 21) and cycle 4 (day 84)</time_frame>
        <population>Pharmacokinetic analysis set. Some patients were excluded from the PK parameter analysis because of missed visits, missed sampling, early termination, dosing outside the planned dose, or lost samples.</population>
        <group_list>
          <group group_id="O1">
            <title>Ph Ib: MCS110 1 mg/kg Q3W + PDR001 100 mg Q3W</title>
            <description>Phase Ib: MCS110 1 mg/kg every 3 weeks (Q3W) + PDR001 100 mg Q3W</description>
          </group>
          <group group_id="O2">
            <title>Ph Ib: MCS110 3 mg/kg Q3W + PDR001 100 mg Q3W</title>
            <description>Phase Ib: MCS110 3 mg/kg Q3W + PDR001 100 mg Q3W</description>
          </group>
          <group group_id="O3">
            <title>Ph Ib: MCS110 3 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 3 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O4">
            <title>Ph Ib: MCS110 5 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 5 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O5">
            <title>Ph Ib: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O6">
            <title>Ph Ib: MCS110 10 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 10 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O7">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - TNBC</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Triple negative breast cancer (TNBC)</description>
          </group>
          <group group_id="O8">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - PC</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Pancreatic cancer (PC)</description>
          </group>
          <group group_id="O9">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - EC</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Endometrial cancer (EC)</description>
          </group>
          <group group_id="O10">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - ME</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Melanoma (ME)</description>
          </group>
        </group_list>
        <measure>
          <title>Phase Ib and Phase II: Pharmacokinetics of PDR001 - T1/2</title>
          <description>Phase Ib and Phase II: PK Parameters - T1/2, which is the terminal half-life associated with the terminal slope of a semi logarithmic concentration time curve (time) - PDR001</description>
          <population>Pharmacokinetic analysis set. Some patients were excluded from the PK parameter analysis because of missed visits, missed sampling, early termination, dosing outside the planned dose, or lost samples.</population>
          <units>day</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="11"/>
                <count group_id="O7" value="20"/>
                <count group_id="O8" value="19"/>
                <count group_id="O9" value="20"/>
                <count group_id="O10" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>T1/2 (day) - cycle 1 - day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="1"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                    <count group_id="O9" value="0"/>
                    <count group_id="O10" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="8.14" lower_limit="8.14" upper_limit="8.14"/>
                    <measurement group_id="O3" value="7.71" lower_limit="7.71" upper_limit="7.71"/>
                    <measurement group_id="O5" value="7.13" lower_limit="7.13" upper_limit="7.13"/>
                    <measurement group_id="O6" value="7.33" lower_limit="7.33" upper_limit="7.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T1/2 (day) - cycle 4 - day 84</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                    <count group_id="O9" value="0"/>
                    <count group_id="O10" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="7.81" lower_limit="7.81" upper_limit="7.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase Ib and Phase II: Pharmacokinetics of MCS110 - CL</title>
        <description>Phase Ib and Phase II: PK Parameters - CL, which is the total body clearance of drug from the plasma (volume × time-1) - MCS110</description>
        <time_frame>cycle 1 (day 21) and cycle 4 (day 84)</time_frame>
        <population>Pharmacokinetic analysis set. Some patients were excluded from the PK parameter analysis because of missed visits, missed sampling, early termination, dosing outside the planned dose, or lost samples.</population>
        <group_list>
          <group group_id="O1">
            <title>Ph Ib: MCS110 1 mg/kg Q3W + PDR001 100 mg Q3W</title>
            <description>Phase Ib: MCS110 1 mg/kg every 3 weeks (Q3W) + PDR001 100 mg Q3W</description>
          </group>
          <group group_id="O2">
            <title>Ph Ib: MCS110 3 mg/kg Q3W + PDR001 100 mg Q3W</title>
            <description>Phase Ib: MCS110 3 mg/kg Q3W + PDR001 100 mg Q3W</description>
          </group>
          <group group_id="O3">
            <title>Ph Ib: MCS110 3 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 3 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O4">
            <title>Ph Ib: MCS110 5 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 5 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O5">
            <title>Ph Ib: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O6">
            <title>Ph Ib: MCS110 10 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 10 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O7">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - TNBC</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Triple negative breast cancer (TNBC)</description>
          </group>
          <group group_id="O8">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - PC</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Pancreatic cancer (PC)</description>
          </group>
          <group group_id="O9">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - EC</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Endometrial cancer (EC)</description>
          </group>
          <group group_id="O10">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - ME</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Melanoma (ME)</description>
          </group>
        </group_list>
        <measure>
          <title>Phase Ib and Phase II: Pharmacokinetics of MCS110 - CL</title>
          <description>Phase Ib and Phase II: PK Parameters - CL, which is the total body clearance of drug from the plasma (volume × time-1) - MCS110</description>
          <population>Pharmacokinetic analysis set. Some patients were excluded from the PK parameter analysis because of missed visits, missed sampling, early termination, dosing outside the planned dose, or lost samples.</population>
          <units>L/h/kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="11"/>
                <count group_id="O7" value="20"/>
                <count group_id="O8" value="19"/>
                <count group_id="O9" value="20"/>
                <count group_id="O10" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CL (L/h/kg) - cycle 1 - day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="5"/>
                    <count group_id="O6" value="5"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                    <count group_id="O9" value="0"/>
                    <count group_id="O10" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000863" spread="0.000158"/>
                    <measurement group_id="O2" value="0.000388" spread="0.000181"/>
                    <measurement group_id="O3" value="0.000394" spread="0.0000833"/>
                    <measurement group_id="O4" value="0.000407" spread="0.000131"/>
                    <measurement group_id="O5" value="0.000338" spread="0.000117"/>
                    <measurement group_id="O6" value="0.000427" spread="0.0000558"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CL (L/h/kg) - cycle 4 - day 84</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="1"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="1"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                    <count group_id="O9" value="0"/>
                    <count group_id="O10" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00117" spread="0.000549"/>
                    <measurement group_id="O2" value="0.000523" spread="0.000199"/>
                    <measurement group_id="O3" value="0.000315" spread="0.000218"/>
                    <measurement group_id="O4" value="0.000337" spread="NA">Not Evaluable</measurement>
                    <measurement group_id="O6" value="0.000541" spread="NA">Not Evaluable</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase Ib and Phase II: Pharmacokinetics of PDR001 - CL</title>
        <description>Phase Ib and Phase II: PK Parameters - CL, which is the total body clearance of drug from the plasma (volume × time-1) - PDR001</description>
        <time_frame>cycle 1 (day 21) and cycle 4 (day 84)</time_frame>
        <population>Pharmacokinetic analysis set. Some patients were excluded from the PK parameter analysis because of missed visits, missed sampling, early termination, dosing outside the planned dose, or lost samples.</population>
        <group_list>
          <group group_id="O1">
            <title>Ph Ib: MCS110 1 mg/kg Q3W + PDR001 100 mg Q3W</title>
            <description>Phase Ib: MCS110 1 mg/kg every 3 weeks (Q3W) + PDR001 100 mg Q3W</description>
          </group>
          <group group_id="O2">
            <title>Ph Ib: MCS110 3 mg/kg Q3W + PDR001 100 mg Q3W</title>
            <description>Phase Ib: MCS110 3 mg/kg Q3W + PDR001 100 mg Q3W</description>
          </group>
          <group group_id="O3">
            <title>Ph Ib: MCS110 3 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 3 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O4">
            <title>Ph Ib: MCS110 5 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 5 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O5">
            <title>Ph Ib: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O6">
            <title>Ph Ib: MCS110 10 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 10 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O7">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - TNBC</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Triple negative breast cancer (TNBC)</description>
          </group>
          <group group_id="O8">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - PC</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Pancreatic cancer (PC)</description>
          </group>
          <group group_id="O9">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - EC</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Endometrial cancer (EC)</description>
          </group>
          <group group_id="O10">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - ME</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Melanoma (ME)</description>
          </group>
        </group_list>
        <measure>
          <title>Phase Ib and Phase II: Pharmacokinetics of PDR001 - CL</title>
          <description>Phase Ib and Phase II: PK Parameters - CL, which is the total body clearance of drug from the plasma (volume × time-1) - PDR001</description>
          <population>Pharmacokinetic analysis set. Some patients were excluded from the PK parameter analysis because of missed visits, missed sampling, early termination, dosing outside the planned dose, or lost samples.</population>
          <units>L/h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="11"/>
                <count group_id="O7" value="20"/>
                <count group_id="O8" value="19"/>
                <count group_id="O9" value="20"/>
                <count group_id="O10" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CL (L/h) - cycle 1 - day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="1"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                    <count group_id="O9" value="0"/>
                    <count group_id="O10" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.0152" spread="NA">Not Evaluable</measurement>
                    <measurement group_id="O3" value="0.0205" spread="NA">Not Evaluable</measurement>
                    <measurement group_id="O5" value="0.0167" spread="NA">Not Evaluable</measurement>
                    <measurement group_id="O6" value="0.0176" spread="NA">Not Evaluable</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CL (L/h) - cycle 4 - day 84</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                    <count group_id="O9" value="0"/>
                    <count group_id="O10" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.0213" spread="NA">Not Evaluable</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase Ib and Phase II: Pharmacokinetics of MCS110 - Vz</title>
        <description>Phase Ib and Phase II: PK Parameters - Vz, which is the apparent volume of distribution during terminal phase (volume) - MCS110</description>
        <time_frame>cycle 1 (day 21) and cycle 4 (day 84)</time_frame>
        <population>Pharmacokinetic analysis set. Some patients were excluded from the PK parameter analysis because of missed visits, missed sampling, early termination, dosing outside the planned dose, or lost samples.</population>
        <group_list>
          <group group_id="O1">
            <title>Ph Ib: MCS110 1 mg/kg Q3W + PDR001 100 mg Q3W</title>
            <description>Phase Ib: MCS110 1 mg/kg every 3 weeks (Q3W) + PDR001 100 mg Q3W</description>
          </group>
          <group group_id="O2">
            <title>Ph Ib: MCS110 3 mg/kg Q3W + PDR001 100 mg Q3W</title>
            <description>Phase Ib: MCS110 3 mg/kg Q3W + PDR001 100 mg Q3W</description>
          </group>
          <group group_id="O3">
            <title>Ph Ib: MCS110 3 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 3 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O4">
            <title>Ph Ib: MCS110 5 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 5 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O5">
            <title>Ph Ib: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O6">
            <title>Ph Ib: MCS110 10 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 10 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O7">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - TNBC</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Triple negative breast cancer (TNBC)</description>
          </group>
          <group group_id="O8">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - PC</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Pancreatic cancer (PC)</description>
          </group>
          <group group_id="O9">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - EC</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Endometrial cancer (EC)</description>
          </group>
          <group group_id="O10">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - ME</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Melanoma (ME)</description>
          </group>
        </group_list>
        <measure>
          <title>Phase Ib and Phase II: Pharmacokinetics of MCS110 - Vz</title>
          <description>Phase Ib and Phase II: PK Parameters - Vz, which is the apparent volume of distribution during terminal phase (volume) - MCS110</description>
          <population>Pharmacokinetic analysis set. Some patients were excluded from the PK parameter analysis because of missed visits, missed sampling, early termination, dosing outside the planned dose, or lost samples.</population>
          <units>L/kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="11"/>
                <count group_id="O7" value="20"/>
                <count group_id="O8" value="19"/>
                <count group_id="O9" value="20"/>
                <count group_id="O10" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Vz (L/kg) - cycle 1 - day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="5"/>
                    <count group_id="O6" value="5"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                    <count group_id="O9" value="0"/>
                    <count group_id="O10" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0486" spread="0.00989"/>
                    <measurement group_id="O2" value="0.0334" spread="0.00783"/>
                    <measurement group_id="O3" value="0.0423" spread="0.00875"/>
                    <measurement group_id="O4" value="0.051" spread="0.0206"/>
                    <measurement group_id="O5" value="0.0651" spread="0.0201"/>
                    <measurement group_id="O6" value="0.065" spread="0.0267"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vz (L/kg) - cycle 4 - day 84</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="1"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="1"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                    <count group_id="O9" value="0"/>
                    <count group_id="O10" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0684" spread="0.0407"/>
                    <measurement group_id="O2" value="0.0294" spread="0.0128"/>
                    <measurement group_id="O3" value="0.045" spread="0.0308"/>
                    <measurement group_id="O4" value="0.0736" spread="NA">Not Evaluable</measurement>
                    <measurement group_id="O6" value="0.0904" spread="NA">Not Evaluable</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase Ib and Phase II: Pharmacokinetics of PDR001 - Vz</title>
        <description>Phase Ib and Phase II: PK Parameters - Vz, which is the apparent volume of distribution during terminal phase (volume) - PDR001</description>
        <time_frame>cycle 1 (day 21) and cycle 4 (day 84)</time_frame>
        <population>Pharmacokinetic analysis set. Some patients were excluded from the PK parameter analysis because of missed visits, missed sampling, early termination, dosing outside the planned dose, or lost samples.</population>
        <group_list>
          <group group_id="O1">
            <title>Ph Ib: MCS110 1 mg/kg Q3W + PDR001 100 mg Q3W</title>
            <description>Phase Ib: MCS110 1 mg/kg every 3 weeks (Q3W) + PDR001 100 mg Q3W</description>
          </group>
          <group group_id="O2">
            <title>Ph Ib: MCS110 3 mg/kg Q3W + PDR001 100 mg Q3W</title>
            <description>Phase Ib: MCS110 3 mg/kg Q3W + PDR001 100 mg Q3W</description>
          </group>
          <group group_id="O3">
            <title>Ph Ib: MCS110 3 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 3 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O4">
            <title>Ph Ib: MCS110 5 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 5 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O5">
            <title>Ph Ib: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O6">
            <title>Ph Ib: MCS110 10 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 10 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O7">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - TNBC</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Triple negative breast cancer (TNBC)</description>
          </group>
          <group group_id="O8">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - PC</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Pancreatic cancer (PC)</description>
          </group>
          <group group_id="O9">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - EC</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Endometrial cancer (EC)</description>
          </group>
          <group group_id="O10">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - ME</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Melanoma (ME)</description>
          </group>
        </group_list>
        <measure>
          <title>Phase Ib and Phase II: Pharmacokinetics of PDR001 - Vz</title>
          <description>Phase Ib and Phase II: PK Parameters - Vz, which is the apparent volume of distribution during terminal phase (volume) - PDR001</description>
          <population>Pharmacokinetic analysis set. Some patients were excluded from the PK parameter analysis because of missed visits, missed sampling, early termination, dosing outside the planned dose, or lost samples.</population>
          <units>Liters (L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="11"/>
                <count group_id="O7" value="20"/>
                <count group_id="O8" value="19"/>
                <count group_id="O9" value="20"/>
                <count group_id="O10" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Vz (L) - cycle 1 - day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="1"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                    <count group_id="O9" value="0"/>
                    <count group_id="O10" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="4.28" spread="NA">Not Evaluable</measurement>
                    <measurement group_id="O3" value="5.47" spread="NA">Not Evaluable</measurement>
                    <measurement group_id="O5" value="4.13" spread="NA">Not Evaluable</measurement>
                    <measurement group_id="O6" value="4.47" spread="NA">Not Evaluable</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vz (L) - cycle 4 - day 84</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                    <count group_id="O9" value="0"/>
                    <count group_id="O10" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="5.76" spread="NA">Not Evaluable</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase Ib and Phase II: Pharmacokinetics of MCS110 - Accumulation Ratio (AR)</title>
        <description>Phase Ib and Phase II: PK Parameters - Accumulation ratio (AR), which is the AUClast (multiple Dose)/AUClast (single dose) (for cycle 4 only) - MCS110</description>
        <time_frame>cycle 4 (day 84)</time_frame>
        <population>Pharmacokinetic analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Ph Ib: MCS110 1 mg/kg Q3W + PDR001 100 mg Q3W</title>
            <description>Phase Ib: MCS110 1 mg/kg every 3 weeks (Q3W) + PDR001 100 mg Q3W</description>
          </group>
          <group group_id="O2">
            <title>Ph Ib: MCS110 3 mg/kg Q3W + PDR001 100 mg Q3W</title>
            <description>Phase Ib: MCS110 3 mg/kg Q3W + PDR001 100 mg Q3W</description>
          </group>
          <group group_id="O3">
            <title>Ph Ib: MCS110 3 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 3 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O4">
            <title>Ph Ib: MCS110 5 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 5 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O5">
            <title>Ph Ib: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O6">
            <title>Ph Ib: MCS110 10 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 10 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O7">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - TNBC</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Triple negative breast cancer (TNBC)</description>
          </group>
          <group group_id="O8">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - PC</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Pancreatic cancer (PC)</description>
          </group>
          <group group_id="O9">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - EC</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Endometrial cancer (EC)</description>
          </group>
          <group group_id="O10">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - ME</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Melanoma (ME)</description>
          </group>
        </group_list>
        <measure>
          <title>Phase Ib and Phase II: Pharmacokinetics of MCS110 - Accumulation Ratio (AR)</title>
          <description>Phase Ib and Phase II: PK Parameters - Accumulation ratio (AR), which is the AUClast (multiple Dose)/AUClast (single dose) (for cycle 4 only) - MCS110</description>
          <population>Pharmacokinetic analysis set</population>
          <units>Ratio of AUC</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="2"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="4"/>
                <count group_id="O10" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.789" spread="0.232"/>
                    <measurement group_id="O2" value="0.744" spread="0.307"/>
                    <measurement group_id="O3" value="0.833" spread="0.0739"/>
                    <measurement group_id="O4" value="1.14" spread="0.0991"/>
                    <measurement group_id="O5" value="1.37" spread="0.278"/>
                    <measurement group_id="O6" value="1.04" spread="0.731"/>
                    <measurement group_id="O7" value="0.712" spread="0.205"/>
                    <measurement group_id="O8" value="0.829" spread="0.177"/>
                    <measurement group_id="O9" value="0.723" spread="0.315"/>
                    <measurement group_id="O10" value="0.987" spread="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase Ib and Phase II: Pharmacokinetics of PDR001 - Accumulation Ratio (AR)</title>
        <description>Phase Ib and Phase II: PK Parameters - Accumulation ratio (AR), which is the AUClast (multiple Dose)/AUClast (single dose) (for cycle 4 only) - PDR001</description>
        <time_frame>cycle 4 (day 84)</time_frame>
        <population>Pharmacokinetic analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Ph Ib: MCS110 1 mg/kg Q3W + PDR001 100 mg Q3W</title>
            <description>Phase Ib: MCS110 1 mg/kg every 3 weeks (Q3W) + PDR001 100 mg Q3W</description>
          </group>
          <group group_id="O2">
            <title>Ph Ib: MCS110 3 mg/kg Q3W + PDR001 100 mg Q3W</title>
            <description>Phase Ib: MCS110 3 mg/kg Q3W + PDR001 100 mg Q3W</description>
          </group>
          <group group_id="O3">
            <title>Ph Ib: MCS110 3 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 3 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O4">
            <title>Ph Ib: MCS110 5 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 5 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O5">
            <title>Ph Ib: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O6">
            <title>Ph Ib: MCS110 10 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 10 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O7">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - TNBC</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Triple negative breast cancer (TNBC)</description>
          </group>
          <group group_id="O8">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - PC</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Pancreatic cancer (PC)</description>
          </group>
          <group group_id="O9">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - EC</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Endometrial cancer (EC)</description>
          </group>
          <group group_id="O10">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - ME</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Melanoma (ME)</description>
          </group>
        </group_list>
        <measure>
          <title>Phase Ib and Phase II: Pharmacokinetics of PDR001 - Accumulation Ratio (AR)</title>
          <description>Phase Ib and Phase II: PK Parameters - Accumulation ratio (AR), which is the AUClast (multiple Dose)/AUClast (single dose) (for cycle 4 only) - PDR001</description>
          <population>Pharmacokinetic analysis set</population>
          <units>Ratio of AUC</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="2"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="5"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="4"/>
                <count group_id="O10" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.48" spread="0.17"/>
                    <measurement group_id="O2" value="1.15" spread="0.522"/>
                    <measurement group_id="O3" value="1.14" spread="0.176"/>
                    <measurement group_id="O4" value="1.89" spread="0.84"/>
                    <measurement group_id="O5" value="1.85" spread="0.348"/>
                    <measurement group_id="O6" value="1.5" spread="0.848"/>
                    <measurement group_id="O7" value="1.08" spread="0.235"/>
                    <measurement group_id="O8" value="1.56" spread="0.593"/>
                    <measurement group_id="O9" value="2.05" spread="0.156"/>
                    <measurement group_id="O10" value="1.54" spread="0.664"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase Ib and Phase II: All Collected Deaths</title>
        <description>On treatment deaths are reported from the start of treatment until end of study treatment plus 30 days, up to maximum duration of 116.4 weeks for phase Ib and 92.4 weeks for phase II. Deaths post treatment survival follow up are reported after the on-treatment period, up to a maximum timeframe of 46 months (3.8 years).</description>
        <time_frame>For ontreatment deaths: up to maximum timeframe of 116.4 weeks for phase Ib and 92.4 weeks for phase II. For total deaths: up to 3.8 years</time_frame>
        <population>Clinical Database Population</population>
        <group_list>
          <group group_id="O1">
            <title>Ph Ib: MCS110 1 mg/kg Q3W + PDR001 100 mg Q3W</title>
            <description>Phase Ib: MCS110 1 mg/kg every 3 weeks (Q3W) + PDR001 100 mg Q3W</description>
          </group>
          <group group_id="O2">
            <title>Ph Ib: MCS110 3 mg/kg Q3W + PDR001 100 mg Q3W</title>
            <description>Phase Ib: MCS110 3 mg/kg Q3W + PDR001 100 mg Q3W</description>
          </group>
          <group group_id="O3">
            <title>Ph Ib: MCS110 3 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 3 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O4">
            <title>Ph Ib: MCS110 5 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 5 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O5">
            <title>Ph Ib: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O6">
            <title>Ph Ib: MCS110 10 mg/kg Q3W + PDR001 300 mg Q3W</title>
            <description>Phase Ib: MCS110 10 mg/kg Q3W + PDR001 300 mg Q3W</description>
          </group>
          <group group_id="O7">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - TNBC</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Triple negative breast cancer (TNBC)</description>
          </group>
          <group group_id="O8">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - PC</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Pancreatic cancer (PC)</description>
          </group>
          <group group_id="O9">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - EC</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Endometrial cancer (EC)</description>
          </group>
          <group group_id="O10">
            <title>Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - ME</title>
            <description>Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Melanoma (ME)</description>
          </group>
        </group_list>
        <measure>
          <title>Phase Ib and Phase II: All Collected Deaths</title>
          <description>On treatment deaths are reported from the start of treatment until end of study treatment plus 30 days, up to maximum duration of 116.4 weeks for phase Ib and 92.4 weeks for phase II. Deaths post treatment survival follow up are reported after the on-treatment period, up to a maximum timeframe of 46 months (3.8 years).</description>
          <population>Clinical Database Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="11"/>
                <count group_id="O7" value="20"/>
                <count group_id="O8" value="20"/>
                <count group_id="O9" value="21"/>
                <count group_id="O10" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total Deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="10"/>
                    <measurement group_id="O7" value="11"/>
                    <measurement group_id="O8" value="19"/>
                    <measurement group_id="O9" value="14"/>
                    <measurement group_id="O10" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>On-treatment Deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="3"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>On-treatment adverse events are reported, from first dose of study treatment until end of study treatment plus 30 days, up to maximum timeframe of 116.4 weeks for phase Ib and 92.4 weeks for phase II.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Ph Ib: MCS110@1 mg/kg Q3W@+ PDR001 100@mg Q3W</title>
          <description>Ph Ib: MCS110@1 mg/kg Q3W@+ PDR001 100@mg Q3W</description>
        </group>
        <group group_id="E2">
          <title>Ph Ib: MCS110@3 mg/kg Q3W@+ PDR001 100@mg Q3W</title>
          <description>Ph Ib: MCS110@3 mg/kg Q3W@+ PDR001 100@mg Q3W</description>
        </group>
        <group group_id="E3">
          <title>Ph Ib: MCS110@3 mg/kg Q3W@+ PDR001 300@mg Q3W</title>
          <description>Ph Ib: MCS110@3 mg/kg Q3W@+ PDR001 300@mg Q3W</description>
        </group>
        <group group_id="E4">
          <title>Ph Ib: MCS110@5 mg/kg Q3W@+ PDR001 300@mg Q3W</title>
          <description>Ph Ib: MCS110@5 mg/kg Q3W@+ PDR001 300@mg Q3W</description>
        </group>
        <group group_id="E5">
          <title>Ph Ib: MCS110@7.5 mg/kg Q3W@+ PDR001 300@mg Q3W</title>
          <description>Ph Ib: MCS110@7.5 mg/kg Q3W@+ PDR001 300@mg Q3W</description>
        </group>
        <group group_id="E6">
          <title>Ph Ib: MCS110@10 mg/kg Q3W@+ PDR001 300@mg Q3W</title>
          <description>Ph Ib: MCS110@10 mg/kg Q3W@+ PDR001 300@mg Q3W</description>
        </group>
        <group group_id="E7">
          <title>Ph II: MCS110@7.5 mg/kg Q3W@+ PDR001 300@mg Q3W - TNBC</title>
          <description>Ph II: MCS110@7.5 mg/kg Q3W@+ PDR001 300@mg Q3W - TNBC</description>
        </group>
        <group group_id="E8">
          <title>Ph II: MCS110@7.5 mg/kg Q3W@+ PDR001 300@mg Q3W - PC</title>
          <description>Ph II: MCS110@7.5 mg/kg Q3W@+ PDR001 300@mg Q3W - PC</description>
        </group>
        <group group_id="E9">
          <title>Ph II: MCS110@7.5 mg/kg Q3W@+ PDR001 300@mg Q3W - EC</title>
          <description>Ph II: MCS110@7.5 mg/kg Q3W@+ PDR001 300@mg Q3W - EC</description>
        </group>
        <group group_id="E10">
          <title>Ph II: MCS110@7.5 mg/kg Q3W@+ PDR001 300@mg Q3W - ME</title>
          <description>Ph II: MCS110@7.5 mg/kg Q3W@+ PDR001 300@mg Q3W - ME</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (23.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="8" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="14" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="8" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="7" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Haemoperitoneum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Large intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Generalised oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Jaundice cholestatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Febrile infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pneumocystis jirovecii pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal procedural complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Infected neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Lymphangiosis carcinomatosa</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Tumour pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Guillain-Barre syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Device breakage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Anuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash papular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (23.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="20" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="20" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="21" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="20" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="7" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypopituitarism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Eye pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Eyelid oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Lacrimation increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Panophthalmitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Periorbital oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="6" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Uveitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Visual impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Xerophthalmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Aphthous ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="5" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Epigastric discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Gingival bleeding</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="8" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="6" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Odynophagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Adverse reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="7" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Face oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="6" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Generalised oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="8" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Suprapubic pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholestasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Portal vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Cytokine release syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Diarrhoea infectious</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Helicobacter infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pyuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Viral skin infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Abdominal injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Post procedural inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Activated partial thromboplastin time prolonged</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="7" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Amylase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="9" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="7" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="13" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="10" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="9" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="10" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="12" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="14" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Blood lactate dehydrogenase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="5" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Blood thyroid stimulating hormone increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Neutrophil count increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="7" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hypermagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hypophagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Vitamin D deficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Groin pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Joint stiffness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Joint warmth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Muscle twitching</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Cancer pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Tumour pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Balance disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Disorientation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Eating disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Choluria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Ureterolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Varicocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Aphonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Lung opacity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Nasal mucosal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Rhinalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hair colour changes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Intertrigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Nail dystrophy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Petechiae</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Rash pruritic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>+ 1 862 778 8300</phone>
      <email>Novartis.email@Novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

